PRIORITY CLAIM

This application claims priority to U.S. Provisional Patent Application Ser. No. 61/091,013, filed Aug. 22, 2008; U.S. Provisional Patent Application Ser. No. 61/096,313, filed Sep. 11, 2008 and U.S. Provisional Patent Application Ser. No. 61/098,739, filed Sep. 19, 2008. The entire contents of each of these priority applications are incorporated herein by reference.

BACKGROUND

Catalysts capable of effecting the copolymerization of epoxides and carbon dioxide to form aliphatic polycarbonates (APCs) have been known in the art since the 1960s. The early catalysts were based on heterogeneous zinc compounds and suffered from low reactivity, a lack of selectivity for polymer formation vs. cyclic carbonate formation, and a tendency to produce polycarbonates contaminated with ether linkages.

Improved catalysts based on transition metals have been discovered over the past decade or so. These newer catalysts have increased reactivity and improved selectivity. Nevertheless, even using highly active catalysts such as those disclosed in U.S. Pat. No. 7,304,172, the reaction times required to make high molecular weight polymer are typically quite long. In addition, the best-performing catalysts disclosed in the '172 patent require the addition of a separate co-catalyst to achieve optimum activity.

Attempts to address these shortcomings have been made. Catalysts described by Nozaki and co-workers (Angew. Chem. Int. Ed. 2006, 45, 7274-7277) tether an amine co-catalyst to a ligand of the catalyst. These next-generation catalytic systems suffer from lengthy and complicated syntheses and undesirable induction times prior to onset of polymerization. There remains a need for catalysts that have increased activity that will further reduce the polymerization time required to produce high molecular weight APCs.

SUMMARY

The present invention provides, among other things, unimolecular catalyst systems having activity in the copolymerization of carbon dioxide and epoxides and methods of using the same. In some embodiments, the present invention provides metal complexes having an activating species with co-catalytic activity tethered to a multidentate ligand that is coordinated to an active metal center of a metal complex.

In certain embodiments, the present invention provides unimolecular metal complexes and methods for using the same in the copolymerization of carbon dioxide and epoxides. In some embodiments, provided metal complexes have the structure:

[Image Omitted]

wherein:

- M is a metal atom;

[Image Omitted]

comprises a multidentate ligand;

- (Z)_mrepresents one or more activating moieties attached to the multidentate ligand, where is a linker moiety covalently coupled to the ligand, each Z is an activating functional group; and m is an integer from 1 to 4 representing the number of Z groups present on an individual linker moiety.

In some embodiments, tethered activating functional groups (Z) are neutral nitrogen-containing moieties. In certain embodiments, neutral nitrogen-containing moieties are selected from the group consisting of:

[Image Omitted]

- or a combination of two or more of these,
  wherein:
- each occurrence of R¹, and R²is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein R¹and R²groups can be taken together with intervening atoms to form one or more optionally substituted rings optionally containing one or more additional heteroatoms;
- each occurrence of R⁵is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein an R⁵group can be taken with an R¹or R²group to form one or more optionally substituted rings; and
- each occurrence of R⁷is independently hydrogen, a hydroxyl protecting group, or an optionally substituted radical selected from the group consisting of C_1-20acyl; C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

In some embodiments, tethered activating functional groups (Z) are cationic moieties. In certain embodiments, cationic moieties are selected from the group consisting of:

[Image Omitted]

or a combination of two or more of these,
wherein:

- each occurrence of R¹, R², and R³is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein any two or more R¹, R², and R³groups can be taken together with intervening atoms to form one or more optionally substituted rings optionally containing one or more additional heteroatoms;
- R⁴is hydrogen or â€”OR⁷;
- R^4â€² is hydrogen, hydroxyl, or optionally substituted C_1-20aliphatic;
- each occurrence of R⁵and R⁶is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein R⁵and R⁶can be taken together with intervening atoms to form one or more optionally substituted rings optionally containing one or more heteroatoms, and an R⁵or R⁶group can be taken with an R¹or R²group to form one or more optionally substituted rings;
- each occurrence of R²is independently hydrogen, a hydroxyl protecting group, or an optionally substituted radical selected from the group consisting of C_1-20acyl; C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- each occurrence of R⁸, R⁹, and R¹⁰is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein any two or more R⁸, R⁹and R¹⁰groups can be taken together with intervening atoms to form one or more optionally substituted rings;
- each occurrence of R¹¹is independently selected from the group consisting of:

halogen, â€”NO₂, â€”CN, â€”SR^y, â€”S(O)R^y, â€”S(O)₂R^y, â€”NR^yC(O)R^y, â€”OC(O)R^y, â€”CO₂R^y, â€”NCO, â€”N₃, â€”OR⁷, â€”OC(O)N(R^y)₂, â€”N(R^y)₂, â€”NR^yC(O)R^y, â€”NR^yC(O)OR^y; or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; where each occurrence of R^yis independently â€”H, or an optionally substituted radical selected from the group consisting of C_1-6aliphatic, 3- to 7-membered heterocyclic, phenyl, and 8- to 10-membered aryl, and where two or more adjacent R¹¹groups can be taken together to form an optionally substituted saturated, partially unsaturated, or aromatic 5- to 12-membered ring containing 0 to 4 heteroatoms;

- X^âˆ’ is any anion, and
- Ring A is an optionally substituted, 5- to 10-membered heteroaryl group.

In some embodiments, an activating functional group (Z) is a phosphorous-containing functional group.

In certain embodiments, a phosphorous-containing functional group is chosen from the group consisting of: phosphines (â€”PR^y₂); Phosphine oxides â€”P(O)R^y₂; phosphinites P(OR⁷)R^y₂; phosphonites P(OR⁷)₂R^y; phosphites P(OR⁷)₃; phosphinates OP(OR⁷)R^y₂; phosphonates; OP(OR⁷)₂R^y; phosphates â€”OP(OR⁷)₃; phosphonium salts ([â€”PR^y₃]⁺) where the phosphorous-containing functional group may be linked to a metal complex through any available position (e.g. direct linkage via the phosphorous atom, or in some cases via an oxygen atom).

In certain embodiments, a phosphorous-containing functional group is chosen from the group consisting of:

[Image Omitted]

or a combination of two or more of these

- wherein R¹and R², are as defined above; and
- each R^7â€² is independently hydrogen, a hydroxyl protecting group, or an optionally substituted radical selected from the group consisting of C_1-20acyl; C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and where two R^7â€² groups can be taken together with intervening atoms to form an optionally substituted ring optionally containing one or more heteroatoms, and an R^7â€² group can be taken with an R¹or R²group to an optionally substituted ring;

In some embodiments, phosphorous containing functional groups include those disclosed in The Chemistry of Organophosphorus Compounds. Volume 4. Ter- and Quinquevalent Phosphorus Acids and their Derivatives. The Chemistry of Functional Group Series Edited by Frank R. Hartley (Cranfield University, Cranfield, U.K.). Wiley: New York. 1996. ISBN 0-471-95706-2, the entirety of which is hereby incorporated herein by reference.

In certain embodiments, a phosphorous-containing functional group has the structure

*â€”(X)_bâ€”[(R⁶R⁷R⁸P)⁺]_nQ^n-, wherein:

X is â€”Oâ€”, â€”Nâ• , or â€”NR^zâ€”,
b is 1 or 0,
each of R⁶, R⁷and R⁸are independently present or absent and, if present, are independently selected from the group consisting of optionally substituted C₁-C₂₀aliphatic, optionally substituted C₆-C₁₄aryl, optionally substituted 3- to 14-membered heterocyclic, optionally substituted 5- to 14-membered heteroaryl, halogen, â• O, â€”OR^z, â• NR^z, and N(R^z)₂where R^zis hydrogen, or an optionally substituted C₁-C₂₀aliphatic, optionally substituted 6- to 14-membered aryl, optionally substituted 3- to 14-membered heterocyclic, or optionally substituted 5- to 14-membered heteroaryl,
Q is any anion, and
n is an integer between 1 and 4.

In some embodiments, the present disclosure encompasses methods for the copolymerization of epoxides and carbon dioxide, such methods comprising contacting one or more epoxides with a catalyst described above in the presence of carbon dioxide.

In some embodiments, the present disclosure encompasses methods for the formation of cyclic carbonates from epoxides and carbon dioxide, such methods comprising contacting one or more epoxides with a catalyst described above in the presence of carbon dioxide.

In some embodiments, the present disclosure encompasses methods for the formation of polyethers, such methods comprising contacting one or more epoxides with a catalyst described above.

DEFINITIONS

Definitions of specific functional groups and chemical terms are described in more detail below. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75^thEd., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March March's Advanced Organic Chemistry, 5^thEdition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; Carruthers, Some Modern Methods of Organic Synthesis, 3^rdEdition, Cambridge University Press, Cambridge, 1987; the entire contents of each of which are incorporated herein by reference.

Certain compounds of the present invention can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and/or diastereomers. Thus, inventive compounds and compositions thereof may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers. In certain embodiments, the compounds of the invention are enantiopure compounds. In certain embodiments, mixtures of enantiomers or diastereomers are provided.

Furthermore, certain compounds, as described herein may have one or more double bonds that can exist as either a Z or E isomer, unless otherwise indicated. The invention additionally encompasses the compounds as individual isomers substantially free of other isomers and alternatively, as mixtures of various isomers, e.g., racemic mixtures of enantiomers. In addition to the above-mentioned compounds per se, this invention also encompasses compositions comprising one or more compounds.

As used herein, the term â€œisomersâ€ includes any and all geometric isomers and stereoisomers. For example, â€œisomersâ€ include cis- and trans-isomers, E- and Z-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. For instance, a compound may, in some embodiments, be provided substantially free of one or more corresponding stereoisomers, and may also be referred to as â€œstereochemically enriched.â€

Where a particular enantiomer is preferred, it may, in some embodiments be provided substantially free of the opposite enantiomer, and may also be referred to as â€œoptically enriched.â€ â€œOptically enriched,â€ as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound is made up of at least about 90% by weight of an enantiomer. In some embodiments the compound is made up of at least about 95%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8%, or 99.9% by weight of an enantiomer. In some embodiments the enantiomeric excess of provided compounds is at least about 90%, 95%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8%, or 99.9%. In some embodiments, enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E. L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind. 1972).

The terms â€œhaloâ€ and â€œhalogenâ€ as used herein refer to an atom selected from fluorine (fluoro, â€”F), chlorine (chloro, â€”Cl), bromine (bromo, â€”Br), and iodine (iodo, â€”I).

The term â€œaliphaticâ€ or â€œaliphatic groupâ€ , as used herein, denotes a hydrocarbon moiety that may be straight-chain (i.e., unbranched), branched, or cyclic (including fused, bridging, and spiro-fused polycyclic) and may be completely saturated or may contain one or more units of unsaturation, but which is not aromatic. Unless otherwise specified, aliphatic groups contain 1-30 carbon atoms. In certain embodiments, aliphatic groups contain 1-12 carbon atoms. In certain embodiments, aliphatic groups contain 1-8 carbon atoms. In certain embodiments, aliphatic groups contain 1-6 carbon atoms. In some embodiments, aliphatic groups contain 1-5 carbon atoms, in some embodiments, aliphatic groups contain 1-4 carbon atoms, in yet other embodiments aliphatic groups contain 1-3 carbon atoms, and in yet other embodiments aliphatic groups contain 1-2 carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, alkyl, alkenyl, and alkynyl groups, and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl. In certain embodiments, the term aliphatic group encompasses aliphatic groups wherein one or more hydrogen atoms are replaced with a halogen atom. In certain embodiments, the term aliphatic group encompasses chlorinated or fluorinated aliphatic groups including perfluorinated compounds.

The term â€œepoxideâ€ , as used herein, refers to a substituted or unsubstituted oxirane. Such substituted oxiranes include monosubstituted oxiranes, disubstituted oxiranes, trisubstituted oxiranes, and tetrasubstituted oxiranes. Such epoxides may be further optionally substituted as defined herein. In certain embodiments, epoxides comprise a single oxirane moiety. In certain embodiments, epoxides comprise two or more oxirane moieties.

The term â€œpolymerâ€ , as used herein, refers to a molecule of high relative molecular mass, the structure of which comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass. In certain embodiments, a polymer is comprised of only one monomer species (e.g., polyethylene oxide). In certain embodiments, a polymer of the present invention is a copolymer, terpolymer, heteropolymer, block copolymer, or tapered heteropolymer of one or more epoxides.

The term â€œunsaturatedâ€ , as used herein, means that a moiety has one or more double or triple bonds.

The terms â€œcycloaliphaticâ€ , â€œcarbocycleâ€ , or â€œcarbocyclicâ€ , used alone or as part of a larger moiety, refer to a saturated or partially unsaturated cyclic aliphatic monocyclic, bicyclic, or polycyclic ring systems, as described herein, having from 3 to 12 members, wherein the aliphatic ring system is optionally substituted as defined above and described herein. Cycloaliphatic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, and cyclooctadienyl. In some embodiments, the cycloalkyl has 3-6 carbons. The terms â€œcycloaliphaticâ€ , â€œcarbocycleâ€ or â€œcarbocyclicâ€ also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as decahydronaphthyl or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring. In some embodiments, a carbocyclic groups is bicyclic. In some embodiments, a carbocyclic group is tricyclic. In some embodiments, a carbocyclic group is polycyclic.

The term â€œalkyl,â€ as used herein, refers to saturated, straight- or branched-chain hydrocarbon radicals derived by removal of a single hydrogen atom from an aliphatic moiety. Unless otherwise specified, alkyl groups contain 1-12 carbon atoms. In certain embodiments, alkyl groups contain 1-8 carbon atoms. In certain embodiments, alkyl groups contain 1-6 carbon atoms. In some embodiments, alkyl groups contain 1-5 carbon atoms, in some embodiments, alkyl groups contain 1-4 carbon atoms, in yet other embodiments alkyl groups contain 1-3 carbon atoms, and in yet other embodiments alkyl groups contain 1-2 carbon atoms. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec-hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, and the like.

The term â€œalkenyl,â€ as used herein, denotes a monovalent group derived by the removal of a single hydrogen atom from a straight- or branched-chain aliphatic moiety having at least one carbon-carbon double bond. Unless otherwise specified, alkenyl groups contain 2-12 carbon atoms. In certain embodiments, alkenyl groups contain 2-8 carbon atoms. In certain embodiments, alkenyl groups contain 2-6 carbon atoms. In some embodiments, alkenyl groups contain 2-5 carbon atoms, in some embodiments, alkenyl groups contain 2-4 carbon atoms, in yet other embodiments alkenyl groups contain 2-3 carbon atoms, and in yet other embodiments alkenyl groups contain 2 carbon atoms. Alkenyl groups include, for example, ethenyl, propenyl, allyl, 1,3-butadienyl, butenyl, 1-methyl-2-buten-1-yl, allyl, 1,3-butadienyl, allenyl, and the like.

The term â€œalkynyl,â€ as used herein, refers to a monovalent group derived by the removal of a single hydrogen atom from a straight- or branched-chain aliphatic moiety having at least one carbon-carbon triple bond. Unless otherwise specified, alkynyl groups contain 2-12 carbon atoms. In certain embodiments, alkynyl groups contain 2-8 carbon atoms. In certain embodiments, alkynyl groups contain 2-6 carbon atoms. In some embodiments, alkynyl groups contain 2-5 carbon atoms, in some embodiments, alkynyl groups contain 2-4 carbon atoms, in yet other embodiments alkynyl groups contain 2-3 carbon atoms, and in yet other embodiments alkynyl groups contain 2 carbon atoms. Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl, and the like.

The term â€œcarbocycleâ€ and â€œcarbocyclic ringâ€ as used herein, refer to monocyclic and polycyclic moieties wherein the rings contain only carbon atoms. Unless otherwise specified, carbocycles may be saturated, partially unsaturated or aromatic, and contain 3 to 20 carbon atoms. Representative carbocyles include cyclopropane, cyclobutane, cyclopentane, cyclohexane, bicyclo[2,2,1]heptane, norbornene, phenyl, cyclohexene, naphthalene, and spiro[4.5]decane, to name but a few.

The term â€œarylâ€ used alone or as part of a larger moiety as in â€œaralkylâ€ , â€œaralkoxyâ€ , or â€œaryloxyalkylâ€ , refers to monocyclic and polycyclic ring systems having a total of six to 20 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to twelve ring members. The term â€œarylâ€ may be used interchangeably with the term â€œaryl ringâ€ . In certain embodiments of the present invention, â€œarylâ€ refers to an aromatic ring system which includes, but is not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term â€œarylâ€ , as it is used herein, is a group in which an aromatic ring is fused to one or more additional rings, such as benzofuranyl, indanyl, phthalimidyl, naphthimidyl, phenantriidinyl, or tetrahydronaphthyl, and the like.

The term â€œheteroaliphatic,â€ as used herein, refers to aliphatic groups wherein one or more carbon atoms are independently replaced by one or more atoms selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus, or boron. In certain embodiments, one to six carbon atoms are independently replaced by one or more of oxygen, sulfur, nitrogen, or phosphorus. Heteroaliphatic groups may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and include saturated, unsaturated or partially unsaturated groups.

The terms â€œheteroarylâ€ and â€œheteroar-â€ , used alone or as part of a larger moiety, e.g., â€œheteroaralkylâ€ , or â€œheteroaralkoxyâ€ , refer to groups having 5 to 14 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 it electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term â€œheteroatomâ€ refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, benzofuranyl and pteridinyl. The terms â€œheteroarylâ€ and â€œheteroar-â€ , as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. A heteroaryl group may be mono- or polycyclic. The term â€œheteroarylâ€ may be used interchangeably with the terms â€œheteroaryl ringâ€ , â€œheteroaryl groupâ€ , or â€œheteroaromaticâ€ , any of which terms include rings that are optionally substituted. The term â€œheteroaralkylâ€ refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.

As used herein, the terms â€œheterocycleâ€ , â€œheterocyclylâ€ , â€œheterocyclic radicalâ€ , and â€œheterocyclic ringâ€ are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-14-membered bicyclic heterocyclic moiety that is saturated, partially unsaturated, or aromatic and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term â€œnitrogenâ€ includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or ⁺NR (as in N-substituted pyrrolidinyl).

A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms â€œheterocycleâ€ , â€œheterocyclylâ€ , â€œheterocyclyl ringâ€ , â€œheterocyclic groupâ€ , â€œheterocyclic moietyâ€ , and â€œheterocyclic radicalâ€ , are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring. A heterocyclyl group may be mono- or bicyclic. The term â€œheterocyclylalkylâ€ refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.

The term â€œacylâ€ as used herein refers to a group having a formula â€”C(O)R where R is hydrogen or an optionally substituted aliphatic, aryl, or heterocyclic group.

As used herein, the term â€œpartially unsaturatedâ€ refers to a ring moiety that includes at least one double or triple bond. The term â€œpartially unsaturatedâ€ is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.

One of ordinary skill in the art will appreciate that the synthetic methods, as described herein, utilize a variety of protecting groups. By the term â€œprotecting group,â€ as used herein, it is meant that a particular functional moiety, e.g., O, S, or N, is masked or blocked, permitting, if desired, a reaction to be carried out selectively at another reactive site in a multifunctional compound. In preferred embodiments, a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group is preferably selectively removable by readily available, preferably non-toxic reagents that do not attack the other functional groups; the protecting group forms a separable derivative (more preferably without the generation of new stereogenic centers); and the protecting group will preferably have a minimum of additional functionality to avoid further sites of reaction. As detailed herein, oxygen, sulfur, nitrogen, and carbon protecting groups may be utilized. By way of non-limiting example, hydroxyl protecting groups include methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxyl)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p,pâ€²-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, Î±-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4â€²-bromophenacyloxyphenyl)diphenylmethyl, 4,4â€²,4â€³-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4â€²,4â€³-tris(levulinoyloxyphenyl)methyl, 4,4â€²,4â€³-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4â€²,4â€³-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1â€²-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-methoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzyl thiocarbonate, 4-ethoxy-1-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o-(methoxycarbonyl)benzoate, Î±-naphthoate, nitrate, alkyl N,N,Nâ€²,Nâ€²-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). For protecting 1,2- or 1,3-diols, the protecting groups include methylene acetal, ethylidene acetal, 1-t-butylethylidene ketal, 1-phenylethylidene ketal, (4-methoxyphenyl)ethylidene acetal, 2,2,2-trichloroethylidene acetal, acetonide, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, benzylidene acetal, p-methoxybenzylidene acetal, 2,4-dimethoxybenzylidene ketal, 3,4-dimethoxybenzylidene acetal, 2-nitrobenzylidene acetal, methoxymethylene acetal, ethoxymethylene acetal, dimethoxymethylene ortho ester, 1-methoxyethylidene ortho ester, 1-ethoxyethylidine ortho ester, 1,2-dimethoxyethylidene ortho ester, Î±-methoxybenzylidene ortho ester, 1-(N,N-dimethylamino)ethylidene derivative, a-(N,Nâ€²-dimethylamino)benzylidene derivative, 2-oxacyclopentylidene ortho ester, di-t-butylsilylene group (DTBS), 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene) derivative (TIPDS), tetra-t-butoxydisiloxane-1,3-diylidene derivative (TBDS), cyclic carbonates, cyclic boronates, ethyl boronate, and phenyl boronate Amino-protecting groups include methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2â€²- and 4â€²-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, phenothiazinyl-(10)-carbonyl derivative, Nâ€²-p-toluenesulfonylaminocarbonyl derivative, Nâ€²-phenylaminothiocarbonyl derivative, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxycarbonylvinyl carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(pâ€²-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, 2,4,6-trimethylbenzyl carbamate, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (Nâ€²-dithiobenzyloxycarbonylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide, o-(benzoyloxymethyl)benzamide, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino Nâ€²-oxide, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, Nâ€”(Nâ€²,Nâ€²-dimethylaminomethylene)amine, N,Nâ€²-isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-[phenyl(pentacarbonylchromium- or tungsten)carbonyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, 3-nitropyridinesulfenamide (Npys), p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), Î²-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4â€²,8â€²-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide. Exemplary protecting groups are detailed herein, however, it will be appreciated that the present invention is not intended to be limited to these protecting groups; rather, a variety of additional equivalent protecting groups can be readily identified using the above criteria and utilized in the method of the present invention. Additionally, a variety of protecting groups are described in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3^rdedition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference.

When substituents are described herein, the term â€œradicalâ€ or â€œoptionally substituted radicalâ€ is sometimes used. In this context, â€œradicalâ€ means a moiety or functional group having an available position for attachment to the structure on which the substituent is bound. In general the point of attachment would bear a hydrogen atom if the substituent were an independent neutral molecule rather than a substituent. The terms â€œradicalâ€ or â€œoptionally-substituted radicalâ€ in this context are thus interchangeable with â€œgroupâ€ or â€œoptionally-substituted groupâ€ .

As described herein, compounds of the invention may contain â€œoptionally substitutedâ€ moieties. In general, the term â€œsubstitutedâ€ , whether preceded by the term â€œoptionallyâ€ or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an â€œoptionally substituted groupâ€ or â€œoptionally substituted radicalâ€ may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term â€œstableâ€ , as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

In some chemical structures herein, substituents are shown attached to a bond that crosses a bond in a ring of the depicted molecule. This convention indicates that one or more of the substituents may be attached to the ring at any available position (usually in place of a hydrogen atom of the parent structure). In cases where an atom of a ring so substituted has two substitutable positions, two groups may be present on the same ring atom. Unless otherwise indicated, when more than one substituent is present, each is defined independently of the others, and each may have a different structure. In cases where the substituent shown crossing a bond of the ring is â€”R, this has the same meaning as if the ring were said to be â€œoptionally substitutedâ€ as described in the preceding paragraph.

Suitable monovalent substituents on a substitutable carbon atom of an â€œoptionally substitutedâ€ group are independently halogen; â€”(CH₂)_0-4R^o; â€”(CH₂)_0-4OR^o; â€”Oâ€”(CH₂)_0-4C(O)OR^o; â€”(CH₂)_0-4CH(OR^o)₂; â€”(CH₂)_0-4SR^o; â€”(CH₂)_0-4Ph, which may be substituted with R^o; â€”(CH₂)_0-4O(CH₂)_0-1Ph which may be substituted with R^o; â€”CHâ• CHPh, which may be substituted with R^o; â€”NO₂; â€”CN; â€”N₃; â€”(CH₂)_0-4N(R^o)₂; â€”(CH₂)_0-4N(R^o)C(O)R^o; â€”N(R^o)C(S)R^o; â€”(CH₂)_0-4N(R^o)C(O)NR^o₂; â€”N(R^o)C(S)NR^o₂; â€”(CH₂)_0-4N(R^o)C(O)OR^o; â€”N(R^o)N(R^o)C(O)R^o; â€”N(R^o)N(R^o)C(O)NR^o₂; â€”N(R^o)N(R^o)C(O)OR^o; â€”(CH₂)_0-4C(O)R^o; â€”C(S)R^o; â€”(CH₂)_0-4C(O)OR^o; â€”(CH₂)_0-4C(O)N(R^o)₂; â€”(CH₂)_0-4C(O)SR^o; â€”(CH₂)_0-4C(O)OSiR^o₃; â€”(CH₂)_0-4OC(O)R^o; â€”OC(O)(CH₂)_0-4SRâ€”, SC(S)SR^o; â€”(CH₂)_0-4SC(O)R^o; â€”(CH₂)_0-4C(O)NR^o₂; â€”C(S)NR^o₂; â€”C(S)SR^o; â€”SC(S)SR^o, â€”(CH₂)_0-4OC(O)NR^o₂; â€”C(O)N(OR^o)R^o; â€”C(O)C(O)R^o; â€”C(O)CH₂C(O)R^o; â€”C(NOR^o)R^o; â€”(CH₂)_0-4SSR^o; â€”(CH₂)_0-4S(O)₂R^o; â€”(CH₂)_0-4S(O)₂OR^o; â€”(CH₂)_0-4OS(O)₂R^o; â€”S(O)₂NR^o₂; â€”(CH₂)_0-4S(O)R^o; â€”N(R^oS(O)₂NR^o₂; â€”N(R^oS(O)₂R^o; â€”N(OR^o)R^o; â€”C(NH)NR^o₂; â€”P(O)₂R^o; â€”P(O)R^o₂; â€”OP(O)R^o₂; â€”OP(O)(OR^o)₂; SiR^o₃; â€”(C_1-4straight or branched)alkylene)Oâ€”N(R^o)₂; or â€”(C_1-4straight or branched) alkylene)C(O)Oâ€”N(R^o)₂, wherein each R^omay be substituted as defined below and is independently hydrogen, C_1-8aliphatic, â€”CH₂Ph, â€”O(CH₂)_0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R^o, taken together with intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono- or polycyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.

Suitable monovalent substituents on R^o(or the ring formed by taking two independent occurrences of R^otogether with their intervening atoms), are independently halogen, â€”(CH₂)_0-2R^î¢, -(haloR^î¢), â€”(CH₂)_0-2OH, â€”(CH₂)_0-2OR^î¢, â€”(CH₂)_0-2CH(OR^î¢)₂; â€”O(haloR^î¢), â€”CN, â€”N₃, â€”(CH₂)_0-2C(O)R^î¢, â€”(CH₂)_0-2C(O)OH, â€”(CH₂)_0-2C(O)OR^î¢, â€”(CH₂)_0-4C(O)N(R^o)₂; â€”(CH₂)_0-2SR^î¢, â€”(CH₂)_0-2SH, â€”(CH₂)_0-2NH₂, â€”(CH₂)_0-2NHR^î¢, â€”(CH₂)_0-2NR^î¢₂, â€”NO₂, â€”SiR^î¢₃, â€”OSiR^î¢₃, â€”C(O)SR^î¢, â€”(C_1-4straight or branched alkylene)C(O)OR^î¢, or â€”SSR^î¢ wherein each R^î¢ is unsubstituted or where preceded by â€œhaloâ€ is substituted only with one or more halogens, and is independently selected from C_1-4aliphatic, â€”CH₂Ph, â€”O(CH₂)_0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R^oinclude â• O and â• S.

Suitable divalent substituents on a saturated carbon atom of an â€œoptionally substitutedâ€ group include the following: â• O, â• S, â• NNR^*₂, â• NNHC(O)R*, â• NNHC(O)OR*, â• NNHS(O)₂R*, â• NR*, â• NOR*, â€”O(C(R*₂))_2-3Oâ€”, or â€”S(C(R*₂))_2-3Sâ€”, wherein each independent occurrence of R* is selected from hydrogen, C_1-6aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an â€œoptionally substitutedâ€ group include: â€”O(CR*₂)_2-3Oâ€”, wherein each independent occurrence of R* is selected from hydrogen, C_1-6aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

Suitable substituents on the aliphatic group of R* include halogen, â€”R^î¢, -(haloR^î¢), â€”OH, â€”OR^î¢, â€”O(haloR^î¢), â€”CN, â€”C(O)OH, â€”C(O)OR^î¢, â€”NH₂, â€”NHR^î¢, â€”NR^î¢₂, or â€”NO₂, wherein each R^î¢ is unsubstituted or where preceded by â€œhaloâ€ is substituted only with one or more halogens, and is independently C_1-4aliphatic, â€”CH₂Ph, â€”O(CH₂)_0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

Suitable substituents on a substitutable nitrogen of an â€œoptionally substitutedâ€ group include â€”R^â€, â€”NR^â€₂, â€”C(O)R^â€, â€”C(O)OR^â€, â€”C(O)C(O)R^â€, â€”C(O)CH₂C(O)R^â€, â€”S(O)₂R^â€, â€”S(O)₂NR^â€₂, â€”C(S)NR^â€₂, â€”C(NH)NR^â€₂, or â€”N(R^â€)S(O)₂R^â€; wherein each R^â€ is independently hydrogen, C_1-6aliphatic which may be substituted as defined below, unsubstituted â€”OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R^â€, taken together with intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. A substitutable nitrogen may be substituted with three R^â€ substituents to provide a charged ammonium moiety â€”N⁺(R^â€)₃, wherein the ammonium moiety is further complexed with a suitable counterion.

Suitable substituents on the aliphatic group of R^â€ are independently halogen, â€”R^î¢, -(haloR^î¢), â€”OH, â€”OR^î¢, â€”O(haloR^î¢), â€”CN, â€”C(O)OH, â€”C(O)OR^î¢, â€”NH₂, â€”NHR^î¢, â€”NR^î¢₂, or â€”NO₂, wherein each R^î¢ is unsubstituted or where preceded by â€œhaloâ€ is substituted only with one or more halogens, and is independently C_1-4aliphatic, â€”CH₂Ph, â€”O(CH₂)_0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

As used herein, the term â€œcatalystâ€ refers to a substance the presence of which increases the rate and/or extent of a chemical reaction, while not being consumed or undergoing a permanent chemical change itself.

As used herein, the term â€œmultidentateâ€ refers to ligands having multiple sites capable of coordinating to a single metal center.

As used herein, the term â€œactivating moietyâ€ refers to a moiety comprising one or more activating functional groups. In certain embodiments, an activating moiety improves the catalytic activity of a metal complex. In some embodiments, such improved catalytic activity is characterized by higher conversion of starting materials compared to a metal complex lacking an activating moiety. In some embodiments, such improved catalytic activity is characterized by higher rate of conversion of starting materials compared to a metal complex lacking an activating moiety. In some embodiments, such improved catalytic activity is characterized by higher yield of product compared to a metal complex lacking an activating moiety.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

The present invention provides, among other things, unimolecular metal complexes for the copolymerization of carbon dioxide and epoxides and methods of using the same. In certain embodiments, provided metal complexes contain a metal-ligand moiety tethered to one or more activating moieties. In some embodiments, an activating moiety comprises a linker and one or more activating functional groups. In some embodiments, provided metal complexes act as polymerization catalysts. In certain embodiments, at least one activating functional group present on the tethered moiety can act as a polymerization co-catalyst and thereby increase the rate of the copolymerization.

[Image Omitted]

wherein:

- M is a metal atom;

[Image Omitted]

comprises a multidentate ligand;

- (Z)_mrepresents one or more activating moieties attached to the multidentate ligand, where is a linker moiety covalently coupled to the ligand, each Z is an activating functional group; and m is an integer from 1 to 4 representing the number of Z groups present on an individual linker moiety.

In certain embodiments, provided metal complexes include a metal atom coordinated to a multidentate ligand and at least one activating moiety tethered to the multidentate ligand. In some embodiments, there are 1 to 10 activating moieties [Image Omitted] (Z)_mtethered to the multidentate ligand. In certain embodiments, there are 1 to 8 such activating moieties tethered to the multidentate ligand. In certain embodiments, there are 1 to 4 such activating moieties tethered to the multidentate ligand.

I. Activating Functional Groups

In some embodiments, an activating functional group is selected from the group consisting of neutral nitrogen-containing functional groups, cationic moieties, phosphorous-containing functional groups, and combinations of two or more of these.

Ia. Neutral Nitrogen-Containing Activating Groups

In some embodiments, one or more tethered activating functional groups on provided metal complexes are neutral nitrogen-containing moieties. In some embodiments, such moieties include one or more of the structures in Table Z-1:

TABLE Z-1

or a combination of two or more of these,

wherein:

- each occurrence of R¹, and R²is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein two or more R¹and R²groups can be taken together with intervening atoms to form one or more optionally substituted rings optionally containing one or more additional heteroatoms;
- each occurrence of R⁵is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein an R⁵group can be taken with an R¹or R²group to form one or more optionally substituted rings;
- each occurrence of R²is independently hydrogen, a hydroxyl protecting group, or an optionally substituted radical selected from the group consisting of C_1-20acyl; C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

In some embodiments, an activating functional group is an N-linked amino group:

[Image Omitted]

where R¹and R²are as defined above.

In certain embodiments, R¹and R²are both hydrogen. In some embodiments, only one of R¹and R²is hydrogen. In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic, 5- to 14-membered heteroaryl, phenyl, 8- to 10-membered aryl and 3- to 7-membered heterocyclic. In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 8- to 10-membered aryl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 5- to 10-membered heteroaryl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 3- to 7-membered heterocyclic.

In certain embodiments, R¹and R²are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, optionally substituted phenyl, or optionally substituted benzyl. In certain embodiments, R¹and R²are both methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, phenyl or benzyl. In some embodiments, R¹and R²are each butyl. In some embodiments, R¹and R²are each isopropyl. In some embodiments, R¹and R²are perfluoro. In some embodiments, R¹and R²are â€”CF₂CF₃. In some embodiments, R¹and R²are each phenyl. In some embodiments, R¹and R²are each benzyl.

In some embodiments, R¹and R²are taken together with intervening atoms to form one or more optionally substituted rings. In certain embodiments, R¹and R²are taken together to form a ring fragment selected from the group consisting of: â€”C(R^y)₂â€”, â€”C(R^y)₂C(R^y)₂â€”, â€”C(R^y)₂C(R^y)₂C(R^y)₂â€”, â€”C(R^y)₂OC(R^y)₂â€”, and â€”C(R^y)₂NR^yC(R^y)₂â€”. In certain embodiments, R¹and R²are taken together to form a ring fragment selected from the group consisting of: â€”CH₂â€”, â€”CH₂CH₂â€”, â€”CH₂CH₂CH₂â€”, â€”CH₂OCH₂â€”, and â€”CH₂NR^yCH₂â€”. In some embodiments, R¹and R²are taken together to form an unsaturated linker moiety optionally containing one or more additional heteroatoms. In some embodiments, the resulting nitrogen-containing ring is partially unsaturated. In certain embodiments, the resulting nitrogen-containing ring comprises a fused polycyclic heterocycle.

In specific embodiments, an N-linked amine activating functional group is selected from the group consisting of:

[Image Omitted]

In some embodiments, one or more activating functional groups is an N-linked hydroxyl amine derivative:

[Image Omitted]

wherein R¹and R⁷are as defined above.

In certain embodiments, R⁷is hydrogen. In some embodiments, R⁷is an optionally substituted radical selected from the group consisting of C_1-12aliphatic, phenyl, 8- to 10-membered aryl, and 3- to 7-membered heterocyclic. In certain embodiments, R⁷is a C_1-12aliphatic. In certain embodiments, R⁷is a C_1-6aliphatic. In some embodiments, R⁷is an optionally substituted 8- to 10-membered aryl group. In certain embodiments, R⁷is an optionally substituted phenyl. In some embodiments, R⁷is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, phenyl or benzyl.

In certain embodiments, R¹is hydrogen. In some embodiments, R¹is an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic, 5- to 14-membered heteroaryl, phenyl, 8- to 10-membered aryl and 3- to 7-membered heterocyclic. In some embodiments, R¹is an optionally substituted radical selected from the group consisting of phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

In some embodiments, R¹is an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, R¹is an optionally substituted C_1-20aliphatic. In certain embodiments, R¹is an optionally substituted C_1-12aliphatic. In some embodiments, R¹is an optionally substituted C_1-6aliphatic. In some embodiments, R¹is an optionally substituted C_1-12heteroaliphatic. In some embodiments, R¹is an optionally substituted 8- to 10-membered aryl. In certain embodiments, R¹is an optionally substituted phenyl. In some embodiments, R¹is an optionally substituted 5- to 10-membered heteroaryl. In some embodiments, R¹is an optionally substituted 3- to 7-membered heterocyclic.

In certain embodiments, R¹is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, phenyl or benzyl. In some embodiments, R¹is butyl. In some embodiments, R¹is isopropyl. In some embodiments, R¹is phenyl. In some embodiments, R¹is benzyl. In some embodiments, R¹is perfluoro. In some embodiments, R¹is â€”CF₂CF₃.

In certain embodiments, R¹and R⁷are taken together with intervening atoms to form one or more optionally substituted rings optionally containing one or more additional heteroatoms.

In certain embodiments, one or more N-linked hydroxyl amine activating functional groups are selected from the group consisting of:

[Image Omitted]

In some embodiments, an activating functional group in a provided metal complex is an amidine. In certain embodiments, such amidine activating functional groups are selected from:

[Image Omitted]

where each occurrence of R¹, R²and R⁵are as defined above.

In certain embodiments, each R¹and R²is hydrogen. In some embodiments, only one of R¹and R²is hydrogen. In certain embodiments, each R¹and R²is independently an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic, 5- to 14-membered heteroaryl, phenyl, 8- to 10-membered aryl and 3- to 7-membered heterocyclic. In some embodiments, each R¹and R²is independently an optionally substituted radical selected from the group consisting of phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 8- to 10-membered aryl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 5- to 10-membered heteroaryl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 3- to 7-membered heterocyclic.

In certain embodiments, R⁵is H. In certain embodiments, R⁵is optionally substituted C_1-20aliphatic. In some embodiments, R⁵is optionally substituted 6- to 14-membered aryl. In certain embodiments, R⁵is optionally substituted C_1-12aliphatic. In some embodiments, R⁵is optionally substituted C_1-6aliphatic. In certain embodiments, R⁵is optionally substituted phenyl.

In some embodiments, one or more R¹or R²groups are taken together with R⁵and intervening atoms to form an optionally substituted ring. In certain embodiments, R¹and R⁵are taken together to form an optionally substituted 5- or 6-membered ring. In some embodiments, R²and R⁵are taken together to form an optionally substituted 5- or 6-membered ring optionally containing one or more additional heteroatoms. In some embodiments, R¹, R²and R⁵are taken together to form an optionally substituted fused ring system. In some embodiments such rings formed by combinations of any of R¹, R²and R⁵are partially unsaturated or aromatic.

In certain embodiments, an activating functional group is an N-linked amidine:

[Image Omitted]

In certain embodiments, N-linked amidine groups are selected from the group consisting of:

[Image Omitted]

In certain embodiments, activating functional groups are amidine moieties linked through the imine nitrogen:

[Image Omitted]

In certain embodiments, imine-linked amidine activating functional groups are selected from the group consisting of:

[Image Omitted]

In certain embodiments, activating functional groups are amidine moieties linked through a carbon atom:

[Image Omitted]

In certain embodiments, carbon-linked amidine activating groups are selected from the group consisting of:

[Image Omitted]

In some embodiments, one or more activating functional groups is a carbamate. In certain embodiments, a carbamate is N-linked:

[Image Omitted]

where R¹and R²are as defined above. In some embodiments, a carbamate is O-linked:

[Image Omitted]

where R¹and R²are as defined above.

In certain embodiments, R¹and R²are both hydrogen. In some embodiments, only one of R¹and R²is hydrogen. In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic, 5- to 14-membered heteroaryl, phenyl, 8- to 10-membered aryl and 3- to 7-membered heterocyclic. In some embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 8- to 10-membered aryl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 5- to 10-membered heteroaryl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 3- to 7-membered heterocyclic.

In some embodiments, an activating functional group is a guanidine or bis-guanidine group:

[Image Omitted]

- where each occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein any two or more R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² groups can be taken together with intervening atoms to form one or more optionally substituted rings optionally containing one or more additional heteroatoms;

In certain embodiments, each occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is hydrogen. In some embodiments, each occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; 3- to 7-membered heterocyclic, phenyl, and 8- to 10-membered aryl. In some embodiments, each occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is hydrogen or an optionally substituted radical selected from the group consisting of phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, each occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic, phenyl, and 8- to 10-membered aryl. In certain embodiments, each occurrence of R¹and R²is independently an optionally hydrogen or an optionally substituted C_1-8aliphatic, phenyl, or 8- to 10-membered aryl group. In some embodiments, each occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is independently hydrogen or an optionally substituted C_1-20aliphatic. In some embodiments, each occurrence of R¹and R²is independently hydrogen an optionally substituted aryl group or an optionally substituted C_1-8aliphatic group. In some embodiments, each occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is independently hydrogen or an optionally substituted C_1-6aliphatic group. In some embodiments, each occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is independently hydrogen or an optionally substituted C_1-4aliphatic group. In some embodiments, each occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² are each independently optionally substituted C_1-6aliphatic. In some embodiments, one or more occurrence of R^1â€², R², R^2â€³, R^2â€³, R³, and R^3â€² is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, one or more occurrence of R¹, R^1â€², R², R^2â€³, R^2â€³, R³, and R^3â€² is independently hydrogen or an optionally substituted phenyl or 8- to 10-membered aryl. In some embodiments, one or more occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is independently hydrogen, or an optionally substituted 5- to 10-membered heteroaryl.

In some embodiments, R¹is optionally substituted C_1-6aliphatic. In certain embodiments, R^1â€² is optionally substituted C_1-6aliphatic. In certain embodiments, R²is optionally substituted C_1-6aliphatic. In certain embodiments, R^2â€² is optionally substituted C_1-6aliphatic. In certain embodiments, R^2â€³ is optionally substituted C_1-6aliphatic. In certain embodiments, R³is optionally substituted C_1-6aliphatic. In certain embodiments, R^3â€² is optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, phenyl or benzyl. In certain embodiments, R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² are each methyl or ethyl. In some embodiments, one or more R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² is perfluoro.

In some embodiments, any two or more R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² groups are taken together with intervening atoms to form one or more optionally substituted rings.

In certain embodiments, R¹and R²are taken together with intervening atoms to form an optionally substituted ring optionally containing one or more additional heteroatoms. In some embodiments, R²and R^2â€² are taken together with intervening atoms to form an optionally substituted ring optionally containing one or more additional heteroatoms. In certain embodiments, R¹and R³are taken together with intervening atoms to form an optionally substituted ring optionally containing one or more additional heteroatoms. In some embodiments, [R²and R^2â€²] and [R¹and R³] are taken together with intervening atoms to form an optionally substituted ring optionally containing one or more additional heteroatoms. In some embodiments, three or more R¹, R^1â€², R², R^2â€², R^2â€³, R³, and R^3â€² groups are taken together with any intervening atoms to form optionally substituted rings. In certain embodiments, R¹and R²groups are taken together to form an optionally substituted 5- or 6-membered ring. In some embodiments, three or more R¹and/or R²groups are taken together to form an optionally substituted fused ring system.

In certain embodiments where an activating functional group is a guanidine or bis guanidine moiety, it is chosen from the group consisting of:

[Image Omitted]

In some embodiments, an activating functional group is a urea:

[Image Omitted]

where R¹, and R²are as defined above.

In certain embodiments, R¹and R²are each hydrogen. In some embodiments, only one of R¹and R²is hydrogen. In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic, phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 8- to 10-membered aryl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 5- to 10-membered heteroaryl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 3- to 7-membered heterocyclic.

In certain embodiments, activating functional groups are oxime or hydrazone groups:

[Image Omitted]

where R¹, R², R⁵, and R⁷are as defined above.

In certain embodiments, R¹and R²are both hydrogen. In some embodiments, only one of R¹and R²is hydrogen. In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic, 5- to 14-membered heteroaryl, 8- to 10-membered aryl and 3- to 7-membered heterocyclic. In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8-to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 8- to 10-membered aryl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 5- to 10-membered heteroaryl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 3- to 7-membered heterocyclic.

In certain embodiments, R⁷is â€”H. In certain embodiments, R⁷is optionally substituted C_1-20aliphatic, while in some embodiments R⁵is optionally substituted 6- to 14-membered aryl. In certain embodiments, R⁷is optionally substituted C_1-12aliphatic or in some embodiments, optionally substituted C_1-6aliphatic. In certain embodiments, R⁷is optionally substituted C_1-12acyl or in some embodiments, optionally substituted C_1-6acyl. In certain embodiments, R⁷is optionally substituted phenyl. In some embodiments, R⁷is a hydroxyl protecting group. In some embodiments, R⁷is a silyl protecting group.

In some embodiments, an activating functional group is an N-oxide derivative:

[Image Omitted]

where R¹and R²are as defined above.

In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 8- to 10-membered aryl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 5- to 10-membered heteroaryl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 3- to 7-membered heterocyclic.

In specific embodiments, an N-oxide activating functional group is selected from the group consisting of:

[Image Omitted]

I.b. Cationic Activating Groups

In some embodiments, one or more tethered activating functional groups on provided metal complexes are cationic moieties include cationic moieties. In some embodiments, such moieties include one or more of the structures in Table Z-2:

TABLE Z-2

or a combination of two or more of these,

wherein:

- each occurrence of R¹, R², and R³is as previously defined;
- R^4â€² is hydrogen, hydroxyl, optionally substituted C_1-20aliphatic;
- each occurrence of R⁵and R⁶is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein R⁵and R⁶can be taken together with intervening atoms to form one or more optionally substituted rings optionally containing one or more heteroatoms, and an R⁵or R⁶group can be taken with an R¹or R²group to form one or more optionally substituted rings;
- each occurrence of R⁸, R⁹, and R¹⁰is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein any two or more R⁸, R⁹and R¹⁰groups can be taken together with intervening atoms to form one or more optionally substituted rings;
- each occurrence of R¹¹is independently selected from the group consisting of:

halogen, â€”NO₂, â€”CN, â€”SR^y, â€”S(O)R^y, â€”S(O)₂R^y, â€”NR^yC(O)R^y, â€”OC(O)R^y, â€”CO₂R^y, â€”NCO, â€”N₃, â€”OR⁷, â€”OC(O)N(R^y)₂, â€”N(R^y)₂, â€”NR^yC(O)R^y, â€”NR^yC(O)OR^y; or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, where each occurrence of R^yis independently hydrogen or an optionally substituted C_1-6aliphatic group, and where two or more adjacent R¹¹groups can be taken together to form an optionally substituted saturated, partially unsaturated, or aromatic 5- to 12-membered ring containing 0 to 4 heteroatoms;

- X^âˆ’ is any anion, and
- Ring A is an optionally substituted, 5- to 10-membered heteroaryl group. In certain embodiments, a cationic activating functional group is a protonated amine:

[Image Omitted]

where R¹and R²are as defined above.

In certain embodiments, R¹and R²are both hydrogen. In some embodiments, only one of R¹and R²is hydrogen. In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic, 5- to 14-membered heteroaryl, phenyl, or 8- to 10-membered aryl and 3- to 7-membered heterocyclic. In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 8- to 10-membered aryl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 5- to 10-membered heteroaryl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 3- to 7-membered heterocyclic.

In specific embodiments, a protonated amine activating functional group is selected from the group consisting of:

[Image Omitted]

In certain embodiments, an activating functional group is a guanidinium group:

[Image Omitted]

In some embodiments, each of R⁴, R⁵, R⁶, R⁷, and R⁸is hydrogen.

In some embodiments, each occurrence of R⁴, R⁵, R⁶, R⁷, and R⁸is independently hydrogen or C_1-20aliphatic. In some embodiments, each occurrence of R⁴, R⁵, R⁶, R⁷, and R⁸is independently hydrogen or C_1-12aliphatic. In some embodiments, each occurrence of R⁴, R⁵, R⁶, R⁷, and R⁸is independently hydrogen or C_1-20heteroaliphatic. In some embodiments, each occurrence of R⁴, R⁵, R⁶, R⁷, and R⁸is independently hydrogen or phenyl. In some embodiments, each occurrence of R⁴, R⁵, R⁶, R⁷, and R⁸is independently hydrogen or 8- to 10-membered aryl. In some embodiments, each occurrence of R⁴, R⁵, R⁶, R⁷, and R⁸is independently hydrogen or 5- to 10-membered heteroaryl. In some embodiments, each occurrence of R⁴, R⁵, R⁶, R⁷, and R⁸is independently hydrogen or 3- to 7-membered heterocyclic. In some embodiments, one or more of R⁴, R⁵, R⁶, and R⁷is optionally substituted C_1-12aliphatic. In certain embodiments, any of (R⁴and R⁵), (R⁵and R⁶), (R⁶and R⁷), (R⁷and R⁸), and (R⁴and R⁷) can be taken together with intervening atoms to form one or more optionally substituted rings. In some embodiments, (R⁴and R⁵) and (R⁶and R⁷) are taken together to form rings.

It will be appreciated that when a guanidinium cation is depicted as

[Image Omitted]

all such resonance forms are contemplated and encompassed by the present disclosure. For example, such groups can also be depicted as

[Image Omitted]

In specific embodiments, a guanidinium activating functional group is selected from the group consisting of:

[Image Omitted]

In some embodiments, an activating functional group is a sulfonium group or an arsonium group:

[Image Omitted]

where R⁸, R⁹, and R¹⁰are as defined above.

In certain embodiments, each occurrence of R⁸, R⁹, and R¹⁰is independently optionally substituted C_1-20aliphatic. In some embodiments, each occurrence of R⁸, R⁹, and R¹⁰is independently hydrogen or optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R⁹, R¹⁰, and R¹¹is independently hydrogen or optionally substituted phenyl. In some embodiments, each occurrence of R⁹, R¹⁰, and R¹¹is independently hydrogen or optionally substituted 8- to 10-membered aryl. In some embodiments, each occurrence of R⁸, R⁹, and R¹⁰is independently hydrogen or optionally substituted 5- to 10-membered heteroaryl. In some embodiments, each occurrence of R⁹, R¹⁰, and R¹¹is independently hydrogen or optionally substituted 3- to 7-membered heterocyclic. In some embodiments, R⁸and R⁹are taken together with intervening atoms to form one or more rings selected from the group consisting of: optionally substituted C₃-C₁₄carbocycle, optionally substituted 3- to 14-membered heterocycle, optionally substituted C₆-C₁₀aryl, and optionally substituted 5- to 10-membered heteroaryl.

In certain embodiments, R⁸, R⁹and R¹⁰are each methyl. In certain embodiments, R⁸, R⁹and R¹⁰are each phenyl.

In specific embodiments, an arsonium activating functional group is selected from the group consisting of:

[Image Omitted]

In some embodiments, an activating functional group is an optionally substituted nitrogen-containing heterocycle. In certain embodiments, the nitrogen-containing heterocycle is an aromatic heterocycle. In certain embodiments, the optionally substituted nitrogen-containing heterocycle is selected from the group consisting of: pyridine, imidazole, pyrrolidine, pyrazole, quinoline, thiazole, dithiazole, oxazole, triazole, pyrazolem, isoxazole, isothiazole, tetrazole, pyrazine, thiazine, and triazine.

In some embodiments, a nitrogen-containing heterocycle includes a quaternarized nitrogen atom. In certain embodiments, a nitrogen-containing heterocycle includes an iminium moiety such as

[Image Omitted]

In certain embodiments, the optionally substituted nitrogen-containing heterocycle is selected from the group consisting of pyridinium, imidazolium, pyrrolidinium, pyrazolium, quinolinium, thiazolium, dithiazolium, oxazolium, triazolium, isoxazolium, isothiazolium, tetrazolium, pyrazinium, thiazinium, and triazinium.

In certain embodiments, a nitrogen-containing heterocycle is linked to a metal complex via a ring nitrogen atom. In some embodiments, a ring nitrogen to which the attachment is made is thereby quaternized, and in some embodiments, linkage to a metal complex takes the place of an Nâ€”H bond and the nitrogen atom thereby remains neutral. In certain embodiments, an optionally substituted N-linked nitrogen-containing heterocycle is a pyridinium derivative. In certain embodiments, optionally substituted N-linked nitrogen-containing heterocycle is an imidazolium derivative. In certain embodiments, optionally substituted N-linked nitrogen-containing heterocycle is a thiazolium derivative. In certain embodiments, optionally substituted N-linked nitrogen-containing heterocycle is a pyridinium derivative.

In some embodiments, an activating functional group is

[Image Omitted]

In certain embodiments, ring A is an optionally substituted, 5- to 10-membered heteroaryl group.

In some embodiments, Ring A is an optionally substituted, 6-membered heteroaryl group. In some embodiments, Ring A is a ring of a fused heterocycle. In some embodiments, Ring A is an optionally substituted pyridyl group.

In some embodiments, R¹²is hydrogen. In some embodiments, R¹²is an optionally substituted C_1-20aliphatic group. In some embodiments, R¹²is C_1-20heteroaliphatic. In some embodiments, R¹²is optionally substituted phenyl, 8- to 10-membered aryl; 5- to 10-membered heteroaryl. In some embodiments, R¹²is 3- to 7-membered heterocyclic. In some embodiments, R¹²is an optionally substituted C_1-12aliphatic group. In some embodiments, R¹²is neopentyl. In some embodiments, R¹²is oxide or hydroxyl.

In some embodiments, when Z is

[Image Omitted]

ring A is other than an imidazole, an oxazole, or a thiazole.

In specific embodiments, a nitrogen-containing heterocycle activating functional group is selected from the group consisting of:

[Image Omitted]

In some embodiments, an activating functional group is

[Image Omitted]

where R¹, R²and R⁵are as defined above.

In certain embodiments, R¹and R²are each hydrogen. In some embodiments, only one of R¹and R²is hydrogen. In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic, 5- to 14-membered heteroaryl, phenyl, 8- to 10-membered aryl and 3- to 7-membered heterocyclic. In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 8- to 10-membered aryl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 5- to 10-membered heteroaryl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 3- to 7-membered heterocyclic.

In certain embodiments, R⁵is H. In certain embodiments, R⁵is optionally substituted C_1-20aliphatic, and in some embodiments R⁵is optionally substituted 6- to 14-membered aryl. In certain embodiments, R⁵is optionally substituted C_1-12aliphatic and in some embodiments, optionally substituted C_1-6aliphatic. In certain embodiments, R⁵is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, phenyl or benzyl. In some embodiments, R⁵is perfluoro. In some embodiments, R⁵is â€”CF₂CF₃. In certain embodiments, R⁵is optionally substituted phenyl.

In some embodiments, an activating functional group is

[Image Omitted]

where R¹and R²are as defined above.

In certain embodiments, R¹and R²are each independently an optionally substituted group selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; and 8-10-membered aryl. In some embodiments, R¹and R²are each independently an optionally substituted 4-7-membered heterocyclic. In some embodiments, R¹and R²can be taken together with intervening atoms to form one or more rings selected from the group consisting of: optionally substituted C₃-C₁₄carbocycle, optionally substituted C₃-C₁₄heterocycle, optionally substituted C₆-C₁₀aryl, and optionally substituted 5- to 10-membered heteroaryl. In some embodiments, R¹and R²are each independently selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, or benzyl. In some embodiments, each occurrence of R¹and R²is independently perfluoro. In some embodiments, each occurrence of R¹and R²is independently â€”CF₂CF₃.

In some embodiments, an activating functional group is

[Image Omitted]

where R¹, R², R³, and R⁵are as defined above.

In certain embodiments, R¹, R², and R³are each independently an optionally substituted group selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; and 8-10-membered aryl. In certain embodiments, R¹, R², and R³are each independently an optionally substituted 4-7-membered heterocyclic. In some embodiments, R¹and R²can be taken together with intervening atoms to form one or more rings selected from the group consisting of: optionally substituted C₃-C₁₄carbocycle, optionally substituted C₃-C₁₄heterocycle, optionally substituted C₆-C₁₀aryl, and optionally substituted 5- to 10-membered heteroaryl. In certain embodiments, R¹, R², and R³are each independently an optionally substituted C_1-6aliphatic. In certain embodiments, R¹, R², and R³are each independently selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, or benzyl. In certain embodiments, R¹, R², and R³are each independently perfluoro. In some embodiments, R¹, R², and R³are each independently â€”CF₂CF₃.

In certain embodiments, R⁵is hydrogen. In certain embodiments R⁵is an optionally substituted group selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, R⁵is an optionally substituted C_1-12aliphatic. In some embodiments, R⁵is optionally substituted C_1-6aliphatic.

In some embodiments, an activating functional group is

[Image Omitted]

In certain embodiments, R⁵and R⁶are each independently an optionally substituted group selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl, and 8-10-membered aryl. In some embodiments, R⁵and R⁶are each independently an optionally substituted C_1-20aliphatic. In some embodiments, R⁵and R⁶are each independently an optionally substituted C_1-20heteroaliphatic having. In some embodiments, R⁵and R⁶are each independently an optionally substituted phenyl or 8-10-membered aryl. In some embodiments, R⁵and R⁶are each independently an optionally substituted 5- to10-membered heteroaryl. In some embodiments, R³and R⁴can be taken together with intervening atoms to form one or more rings selected from the group consisting of: optionally substituted C₃-C₁₄carbocycle, optionally substituted C₃-C₁₄heterocycle, optionally substituted C₆-C₁₀aryl, and optionally substituted 5- to 10-membered heteroaryl. In some embodiments, R⁵and R⁶are each independently an optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R⁵and R⁶is independently methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, or benzyl. In some embodiments, each occurrence of R⁵and R⁶is independently perfluoro. In some embodiments, each occurrence of R⁵and R⁶is independently â€”CF₂CF₃.

In some embodiments, an activating functional group is

[Image Omitted]

where R¹and R²are as defined above.

In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl or 8- to 10-membered aryl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 5- to 10-membered heteroaryl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 3- to 7-membered heterocyclic.

In some embodiments, an activating functional group is

[Image Omitted]

In some embodiments, an activating functional group is

[Image Omitted]

where R¹and R²are as defined above.

In certain embodiments, R¹and R²are each independently an optionally substituted radical selected from the group consisting of C_1-12aliphatic and C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-12aliphatic. In some embodiments, R¹and R²are each independently optionally substituted C_1-6aliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-20heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted C_1-12heteroaliphatic. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 8- to 10-membered aryl. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted phenyl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 5- to 10-membered heteroaryl group. In some embodiments, each occurrence of R¹and R²is independently an optionally substituted 3- to 7-membered heterocyclic.

In some embodiments, an activating functional group is

[Image Omitted]

In some embodiments, an activating functional group is

[Image Omitted]

In some embodiments, an activating functional group is

[Image Omitted]

where R¹and R²are as defined above.

R²are each independently selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, or benzyl. In some embodiments, each occurrence of R¹and R²is independently perfluoro. In some embodiments, each occurrence of R¹and R²is independently â€”CF₂CF₃.

In certain embodiments, X is any anion. In certain embodiments, X is a nucleophile. In some embodiments, X is a nucleophile capable of ring opening an epoxide. In certain embodiments, X is absent. In certain embodiments, X is a nucleophilic ligand. Exemplary nucleophilic ligands include, but are not limited to, â€”OR^x, â€”SR^x, â€”O(Câ• O)R^x, â€”O(Câ• O)OR^x, â€”O(Câ• O)N(R^x)₂, â€”N(R^x)(Câ• O)R^x, â€”NC, â€”CN, halo (e.g., â€”Br, â€”I, â€”Cl), â€”N₃, â€”O(SO₂)R^xand â€”OPR^x₃, wherein each R^xis, independently, selected from hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl and optionally substituted heteroaryl.

In certain embodiments, X is â€”O(Câ• O)R^x, wherein R^xis selected from optionally substituted aliphatic, fluorinated aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, fluorinated aryl, and optionally substituted heteroaryl.

For example, in certain embodiments, X is â€”O(Câ• O)R^x, wherein R^xis optionally substituted aliphatic. In certain embodiments, X is â€”O(Câ• O)R^x, wherein R^xis optionally substituted alkyl and fluoroalkyl. In certain embodiments, X is â€”O(Câ• O)CH₃or â€”O(Câ• O)CF₃.

Furthermore, in certain embodiments, X is â€”O(Câ• O)R^x, wherein R^xis optionally substituted aryl, fluoroaryl, or heteroaryl. In certain embodiments, X is â€”O(Câ• O)R^x, wherein R^xis optionally substituted aryl. In certain embodiments, X is â€”O(Câ• O)R^x, wherein R^xis optionally substituted phenyl. In certain embodiments, X is â€”O(Câ• O)C₆H₅or â€”O(Câ• O)C₆F₅.

In certain embodiments, X is â€”OR^x, wherein R^xis selected from optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, and optionally substituted heteroaryl.

For example, in certain embodiments, X is â€”OR^x, wherein R^xis optionally substituted aryl. In certain embodiments, X is â€”OR^x, wherein R^xis optionally substituted phenyl. In certain embodiments, X is â€”OC₆H₅or â€”OC₆H₂(2,4-NO₂).

In certain embodiments, X is halo. In certain embodiments, X is â€”Br. In certain embodiments, X is â€”Cl. In certain embodiments, X is â€”I.

In certain embodiments, X is â€”O(SO₂)R^x. In certain embodiments X is â€”OTs. In certain embodiments X is â€”OSO₂Me. In certain embodiments X is â€”OSO₂CF₃. In some embodiments, X is a 2,4-dinitrophenolate anion.

I.c. Phosphorous-Containing Activating Groups

In some embodiments, activating functional groups Z are phosphorous containing groups.

In certain embodiments, a phosphorous-containing functional group is chosen from the group consisting of: phosphines (â€”PR^y₂); Phosphine oxides â€”P(O)R^y₂; phosphinites P(OR⁷)R^y₂; phosphonites P(OR⁷)₂R^y; phosphites P(OR⁷)₃; phosphinates OP(OR⁷)R^y₂; phosphonates; OP(OR⁷)₂R^y; phosphates â€”OP(OR⁷)₃; phosponium salts ([â€”PR^y₃]⁺) where a phosphorous-containing functional group may be linked to a metal complex through any available position (e.g. direct linkage via the phosphorous atom, or in some cases via an oxygen atom).

In certain embodiments, a phosphorous-containing functional group is chosen from the group consisting of:

[Image Omitted]

or a combination of two or more of these

- wherein R¹and R², are as defined above; and
- each R^7â€², is independently hydrogen, a hydroxyl protecting group, or an optionally substituted radical selected from the group consisting of C_1-20acyl; C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and where two R^7â€² groups can be taken together with intervening atoms to form an optionally substituted ring optionally containing one or more heteroatoms, and an R⁷group can be taken with an R¹or R²group to an optionally substituted ring;

*â€”(X)_bâ€”[(R⁶R⁷R⁸P)⁺]_nQ^n-,wherein:

X is â€”Oâ€”, â€”Nâ• , or â€”NR^zâ€”,
b is 1 or 0,
each of R⁶, R⁷and R⁸are independently present or absent and, if present, are independently selected from the group consisting of optionally substituted C₁-C₂₀aliphatic, optionally substituted phenyl, optionally substituted C₈-C₁₄aryl, optionally substituted 3- to 14-membered heterocyclic, optionally substituted 5- to 14-membered heteroaryl, halogen, â• O, â€”OR^z, â• NR^z, and N(R^z)₂where R^zis hydrogen, or an optionally substituted C₁-C₂₀aliphatic, optionally substituted phenyl, optionally substituted 8- to 14-membered aryl, optionally substituted 3- to 14-membered heterocyclic, or optionally substituted 5- to 14-membered heteroaryl,
Q is any anion, and
n is an integer between 1 and 4.

In some embodiments, an activating functional group is a phosphonate group:

[Image Omitted]

wherein R¹, R², and R^7â€² is as defined above.

In specific embodiments, a phosphonate activating functional group is selected from the group consisting of:

[Image Omitted]

In some embodiments, an activating functional group is a phosphonic diamide group:

[Image Omitted]

wherein R¹, R², and R^7â€², are as defined above. In certain embodiments, each R¹and R²group in a phosphonic diamide is methyl.

In some embodiments an activating functional group is a phosphine group:

[Image Omitted]

wherein R¹, and R²are as defined above.

In specific embodiments, a phosphine activating functional group is selected from the group consisting of:

[Image Omitted]

II. Linker Moieties

As described above, each activating moiety [Image Omitted] (Z)_mcomprises a linker coupled to at least one activating functional group Z as described above, with m denoting the number of activating functional groups present on a single linker moiety.

As noted above there may be one or more activating moiety [Image Omitted] (Z)_mtethered to a given metal complex, similarly, each activating moiety itself may contain more than one activating functional group Z. In certain embodiments, each activating moiety contains only one activating functional group (i.e. m=1). In some embodiments, each activating moiety contains more than one activating functional groups (i.e. m>1). In certain embodiments, an activating moiety contains two activating functional groups (i.e. m=2). In certain embodiments, an activating moiety contains three activating functional groups (i.e. m=3). In certain embodiments, an activating moiety contains four activating functional groups (i.e. m=4). In certain embodiments where more than one activating functional group is present on an activating moiety, they are all the same functional group. In some embodiments where more than one activating functional group is present on an activating moiety, two or more of the activating functional groups are different.

In certain embodiments, each linker moiety [Image Omitted] contains 1-30 atoms including at least one carbon atom, and optionally one or more atoms selected from the group consisting of N, O, S, Si, B, and P.

In certain embodiments, the linker is an optionally substituted C_2-30aliphatic group wherein one or more methylene units are optionally and independently replaced by â€”NR^yâ€”, â€”N(R^y)C(O)â€”, â€”C(O)N(R^y)â€”, â€”Oâ€”, â€”C(O)â€”, â€”OC(O)â€”, â€”C(O)Oâ€”, â€”Sâ€”, â€”SOâ€”, â€”SO₂â€”, â€”C(â• S)â€”, â€”C(â• NR^y)â€”, or â€”Nâ• Nâ€”, where each occurrence of R^yis independently â€”H, or an optionally substituted radical selected from the group consisting of C_1-6aliphatic 3- to 7-membered heterocyclic, phenyl, and 8- to 10-membered aryl. In certain embodiments, a linker moiety is a C₄-C₁₂aliphatic group substituted with one or more moieties selected from the group consisting of halogen, â€”NO₂, â€”CN, â€”SR^y, â€”S(O)R^y, â€”S(O)₂R^y, â€”NR^yC(O)R^y, â€”OC(O)R^y, â€”CO₂R^y, â€”NCO, â€”N₃, â€”OR⁷, â€”OC(O)N(R^y)₂, â€”N(R^y)₂, â€”NR^yC(O)R^y, and â€”NR^yC(O)OR^y, where R^yis â€”H, or an optionally substituted radical selected from the group consisting of C_1-6aliphatic 3- to 7-membered heterocyclic, phenyl, and 8- to 10-membered aryl.

In certain embodiments, a linker moiety is an optionally substituted C₃-C₃₀aliphatic group. In certain embodiments, a linker is an optionally substituted C_4-24aliphatic group. In certain embodiments, a linker moiety is an optionally substituted C₄-C₂₀aliphatic group. In certain embodiments, a linker moiety is an optionally substituted C₄-C₁₂aliphatic group. In certain embodiments, a linker is an optionally substituted C_4-10aliphatic group. In certain embodiments, a linker is an optionally substituted C_4-8aliphatic group. In certain embodiments, a linker moiety is an optionally substituted C₄-C₆aliphatic group. In certain embodiments, a linker moiety is an optionally substituted C₆-C₁₂aliphatic group. In certain embodiments, a linker moiety is an optionally substituted C₈aliphatic group. In certain embodiments, a linker moiety is an optionally substituted C₇aliphatic group. In certain embodiments, a linker moiety is an optionally substituted C₆aliphatic group. In certain embodiments, a linker moiety is an optionally substituted C₅aliphatic group. In certain embodiments, a linker moiety is an optionally substituted C₄aliphatic group. In certain embodiments, a linker moiety is an optionally substituted C₃aliphatic group. In certain embodiments, a aliphatic group in the linker moiety is an optionally substituted straight alkyl chain. In certain embodiments, the aliphatic group is an optionally substituted branched alkyl chain. In some embodiments, a linker moiety is a C₄to C₂₀alkyl group having one or more methylene groups replaced by â€”C(R^aR^b)â€” where R^aand R^bare each, independently C₁-C₄alkyl groups. In certain embodiments, a linker moiety consists of an aliphatic group having 4 to 30 carbons including one or more gem-dimethyl substituted carbon atoms.

In certain embodiments, a linker moiety includes one or more optionally substituted cyclic elements selected from the group consisting of saturated or partially unsaturated carbocyclic, aryl, heterocyclic, or heteroaryl. In certain embodiments, a linker moiety consists of the substituted cyclic element, in some embodiments the cyclic element is part of a linker with one or more non-ring heteroatoms or optionally substituted aliphatic groups comprising other parts of the linker moiety.

In some embodiments, a linker moiety is of sufficient length to allow one or more activating functional groups to be positioned near a metal atom of a metal complex. In certain embodiments, structural constraints are built into a linker moiety to control the disposition and orientation of one or more activating functional groups near a metal center of a metal complex. In certain embodiments such structural constraints are selected from the group consisting of cyclic moieties, bicyclic moieties, bridged cyclic moieties and tricyclic moieties. In some embodiments, such structural constraints are the result of acyclic steric interactions. In certain embodiments such structural constraints are selected from the group consisting of cis double bonds, trans double bonds, cis allenes, trans allenes, and triple bonds. In some embodiments, such structural constraints are selected from the group consisting of substituted carbons including geminally disubstituted groups such as sprirocyclic rings, gem dimethyl groups, gem diethyl groups and gem diphenyl groups. In certain embodiments such structural constraints are selected from the group consisting of heteratom-containing functional groups such as sulfoxides, amides, and oximes.

In certain embodiments, linker moieties are selected from the group consisting of:

[Image Omitted]

where * represents the site of attachment to a ligand, and each # represents a site of attachment of an activating functional group.

In some embodiments, s is 0. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, s is 3. In some embodiments, s is 4. In some embodiments, s is 5. In some embodiments, s is 6.

In some embodiments, t is 1. In some embodiments, t is 2. In some embodiments, t is 3. In some embodiments, t is 4.

III. Metal Complexes

As noted above, the present invention encompasses metal complexes that include a metal atom coordinated to a multidentate ligand and at least one activating moiety tethered to a multidentate ligand. In certain embodiments, provided metal complexes have the structure:

[Image Omitted]

where

[Image Omitted]

represents a metal atom coordinated to a multidentate ligand.
IIa. Metal Atoms

In certain embodiments, M is a metal atom selected from periodic table groups 3-13, inclusive. In certain embodiments, M is a transition metal selected from periodic table groups 5-12, inclusive. In certain embodiments, M is a transition metal selected from periodic table groups 4-11, inclusive. In certain embodiments, M is a transition metal selected from periodic table groups 5-10, inclusive. In certain embodiments, M is a transition metal selected from periodic table groups 7-9, inclusive. In some embodiments, M is selected from the group consisting of Cr, Mn, V, Fe, Co, Mo, W, Ru, Al, and Ni. In some embodiments, M is a metal atom selected from the group consisting of: cobalt; chromium; aluminum; titanium; ruthenium, and manganese. In some embodiments, M is cobalt. In some embodiments, M is chromium. In some embodiments, M is aluminum.

In certain embodiments, a metal complex is a zinc, cobalt, chromium, aluminum, titanium, ruthenium, or manganese complex. In certain embodiments, a metal complex is an aluminum complex. In some embodiments, a metal complex is a chromium complex.

In some embodiments, a metal complex is a zinc complex. In certain some embodiments, a metal complex is a titanium complex. In some embodiments, a metal complex is a ruthenium complex. In certain embodiments, a metal complex is a manganese complex. In certain embodiments, a metal complex is cobalt complex. In certain embodiments where the metal complex is a cobalt complex, the cobalt metal has an oxidation state of 3+ (i.e., Co(III)). In some embodiments, the cobalt metal has an oxidation state of 2+.

IILb. Ligands

In some embodiments, a metal complex

[Image Omitted]

comprises a metal atom coordinated to a single tetradentate ligand and in some embodiments, the metal complex comprises a chelate containing a plurality of individual ligands. In certain embodiments, a metal complex contains two bidentate ligands. In some embodiments, a metal complex contains a tridentate ligand.

In various embodiments, tetradentate ligands suitable for metal complexes of the present invention may include, but are not limited to: salen derivatives 1, derivatives of salan ligands 2, bis-2-hydroxybenzamido derivatives 3, derivatives of the Trost ligand 4, porphyrin derivatives 5, derivatives of tetrabenzoporphyrin ligands 6, derivatives of corrole ligands 7, phthalocyaninate derivatives 8, and dibenzotetramethyltetraaza[14]annulene (tmtaa) derivatives 9 or 9â€².

[Image Omitted]

In some embodiments, a metal multidentate ligand coordinated with a metal complex may comprise a plurality of discrete ligands. In some embodiments, metal complexes include two bidentate ligands. In certain embodiments, such bidentate ligands may have the structure

[Image Omitted]

where R^dand R^lare as defined above. Metal complexes having two such ligands may adopt one of several geometries, and the present disclosure encompasses such variations.

In certain embodiments, metal complexes including two bidentate ligands may have structures selected from the group consisting of:

[Image Omitted]

where each

[Image Omitted]

represents a ligand:

[Image Omitted]

In certain embodiments, a tetradentate ligand is a salen ligand. In certain embodiments, a metal complex is a metallosalenate. In certain embodiments, a metal complex is a cobalt salen complex. In certain embodiments, a metal complex is a chromium salen complex. In some embodiments, a metal complex is an aluminum salen complex.

In certain embodiments, at least one activating moiety is tethered to a carbon atom of a phenyl ring of the salicylaldehyde-derived portions of a salen ligand. In certain embodiments, at least one activating moiety is tethered to a carbon atom of a porphyrin ligand. In certain embodiments, at least one activating moiety is tethered to a pyrrole-carbon atom of a porphyrin ligand. In certain embodiments, at least one activating moiety is tethered to a carbon atom forming the bridge between the pyrrole rings of a porphyrin ligand.

In certain embodiments, at least one activating moiety is tethered to one or more carbon atoms of only one phenyl ring of the salicylaldehyde-derived portions of a salen ligand, as shown in formula I:

[Image Omitted]

wherein:

- M is a metal atom;
- X is a nucleophile capable of ring opening an epoxide;
- k is an integer from 0-2 inclusive;
- Râ€² represents one or more substituents optionally present on the phenyl rings and each Râ€² is independently selected from the group consisting of: halogen, â€”NO₂, â€”CN, â€”SR^y, â€”S(O)R^y, â€”S(O)₂R^y, â€”NR^yC(O)R^y, â€”OC(O)R^y, â€”CO₂R^y, â€”NCO, â€”N₃, â€”OR⁷, â€”OC(O)N(R^y)₂, â€”N(R^y)₂, â€”NR^yC(O)R^y, â€”NR^yC(O)OR^y; or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, where two or more adjacent Râ€² groups can be taken together to form an optionally substituted saturated, partially unsaturated, or aromatic 5- to 12-membered ring containing 0 to 4 heteroatoms;
- R^yis â€”H, or an optionally substituted radical selected from the group consisting of

C_1-6aliphatic, 3- to 7-membered heterocyclic, phenyl, and 8- to 10-membered aryl;

[Image Omitted]

- represents is an optionally substituted moiety linking the two nitrogen atoms of the diamine portion of the salen ligand, where

[Image Omitted]

- â€ƒis selected from the group consisting of phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an optionally substituted C_2-20aliphatic group, wherein one or more methylene units are optionally and independently replaced by â€”NR^yâ€”, â€”N(R^y)C(O)â€”, â€”C(O)N(R^y)â€”, â€”OC(O)N(R^y)â€”, â€”N(R^y)C(O)Oâ€”, â€”OC(O)Oâ€”, â€”Oâ€”, â€”C(O)â€”, â€”OC(O)â€”, â€”C(O)Oâ€”, â€”Sâ€”, â€”SOâ€”, â€”SO₂â€”, â€”C(â• S)â€”, â€”C(â• NR^y)â€”, â€”C(â• NOR^y)â€” or â€”Nâ• Nâ€”;
- (Z)_mrepresents one or more activating moieties, where â€œâ€ is a covalent linker containing one or more atoms selected from the group consisting of C, O, N, S, and Si; Z is a activating functional group and m is an integer from 1 to 4 indicating the number of individual activating functional groups present in each activating moiety.

In certain embodiments, both salicylaldehyde-derived portions of a salen ligand bear one or more activating moieties:

[Image Omitted]

wherein M, X, k, Râ€²,

[Image Omitted]

and [Image Omitted] (Z)_mare as defined above.

In some embodiments, provided metal complexes comprise a

[Image Omitted]

moiety that has the structure:

[Image Omitted]

wherein:

- M is a metal atom,
- R^1a, R^1aâ€², R^2a, R^2aâ€², R^3a, and R^3aâ€² are independently a (Z)_mgroup, hydrogen, halogen, â€”OR, â€”NR₂, â€”SR, â€”CN, â€”NO₂, â€”SO₂R, â€”SOR, â€”SO₂NR₂; â€”CNO, â€”NRSO₂R, â€”NCO, â€”N₃, â€”SiR₃; or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- each R is independently hydrogen, an optionally substituted radical selected the group consisting of acyl; carbamoyl; arylalkyl; phenyl, 8- to 10-membered aryl; C_1-12aliphatic; C_1-12heteroaliphatic; 5- to 10-membered heteroaryl; 4- to 7-membered heterocyclyl; an oxygen protecting group; and a nitrogen protecting group; or:
  - two R on the same nitrogen atom are taken with the nitrogen to form a 3- to 7-membered heterocyclic ring;
- wherein any of [R^2aâ€² and R^3aâ€²], [R^2aand R^3a], [R^1aand R^2a], and [R^1aâ€² and R^2aâ€²] may optionally be taken together with the carbon atoms to which they are attached to form one or more rings which may in turn be substituted with one or more R^20agroups; and
- R^4ais selected from the group consisting of:
  - a)

[Image Omitted]

- - b)

[Image Omitted]

- - c)

[Image Omitted]

- - â€ƒand
  - d)

[Image Omitted]

- - â€ƒwhere
  - R^cat each occurrence is independently a Z group, hydrogen, halogen, â€”OR, â€”NR₂, â€”SR, â€”CN, â€”NO₂, â€”SO₂R, â€”SOR, â€”SO₂NR₂; â€”CNO, â€”NRSO₂R, â€”NCO, â€”N₃, â€”SiR₃; or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  - - where:
      - two or more R^cgroups may be taken together with the carbon atoms to which they are attached and any intervening atoms to form one or more rings;
      - when two R^cgroups are attached to the same carbon atom, they may be taken together along with the carbon atom to which they are attached to form a moiety selected from the group consisting of: a 3- to 8-memberedspirocyclic ring, a carbonyl, an oxime, a hydrazone, an imine;
- X is a nucleophile capable of ring opening an epoxide;
- Y is a divalent linker selected from the group consisting of: â€”NRâ€”, â€”N(R)C(O)â€”, â€”C(O)NRâ€”, â€”Oâ€”, â€”C(O)â€”, â€”OC(O)â€”, â€”C(O)Oâ€”, â€”Sâ€”, â€”SOâ€”, â€”SO₂â€”, â€”C(â• S)â€”, â€”C(â• NR)â€”, or â€”Nâ• Nâ€”; a polyether; a C₃to C₈substituted or unsubstituted carbocycle; and a C₁to C₈substituted or unsubstituted heterocycle;
- mâ€² is 0 or an integer from 1 to 4, inclusive;
- q is 0 or an integer from 1 to 4, inclusive; and
- x is 0, 1, or 2.

In some embodiments, at least one of [R^2aand R^3a] and [R^2aâ€² and R^3aâ€²] are taken together to form a ring. In some embodiments, both [R^2aand R^3a] and [R^2aâ€² and R^3aâ€²] are taken together to form rings. In some embodiments, the rings formed by [R^2aand R^3a] and [R^2aâ€² and R^3aâ€²] are substituted phenyl rings.

In certain embodiments, one or more of R^1a, R^1aâ€², R^2a, R^2aâ€², R^3a, and R^3aâ€² are independently a [Image Omitted] Z group.

In certain embodiments of provided metal complexes, a

[Image Omitted]

moiety has a structure selected from the group consisting of:

[Image Omitted]

wherein:

- M is a metal atom;
- R^4a, R^4aâ€², R^5a, R^5aâ€², R^6a, R^6aâ€², R^7a, and R^7aâ€² are each independently a Z group, hydrogen, halogen, â€”OR, â€”NR₂, â€”SR, â€”CN, â€”NO₂, â€”SO₂R, â€”SOR, â€”SO₂NR₂; â€”CNO, â€”NRSO₂R, â€”NCO, â€”N_i, â€”SiR₃; or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- wherein [R^1aand R^4a], [R^1aâ€² and R^4aâ€²] and any two adjacent R^4a, R^4aâ€², R^5a, R^5aâ€², R^6a, R^6aâ€², R^7a, and R^7aâ€² groups can be taken together with intervening atoms to form one or more optionally substituted rings;
- n is 0 or an integer from 1 to 8, inclusive; and
- p is 0 or an integer from 1 to 4, inclusive.

In some embodiments, M is Co.

In some embodiments, R^1a, R^1aâ€², R^4a, R^4aâ€², R^6a, and R^6aâ€² are each â€”H. In some embodiments, R^5a, R^5aâ€², R^7aand R^7aâ€² are each optionally substituted C₁-C₁₂aliphatic. In some embodiments, R^4a, R^4aâ€², R^5a, R^5aâ€², R^6a, R^6aâ€², R^7a, and R^7aâ€² are each independently selected from the group consisting of: â€”H, â€”SiR₃; methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, t-butyl, isoamyl, t-amyl, thexyl, and trityl. In some embodiments, R^1a, R^1aâ€², R^4a, R^4aâ€², R^6a, and R^6aâ€² are each â€”H. In some embodiments, R^7ais selected from the group consisting of â€”H; methyl; ethyl; n-propyl; i-propyl; n-butyl; sec-butyl; t-butyl; isoamyl; t-amyl; thexyl; and trityl. In some embodiments, R^5aand R^7aare independently selected from the group consisting of â€”H; methyl; ethyl; n-propyl; i-propyl; n-butyl; sec-butyl; t-butyl; isoamyl; t-amyl; thexyl; and trityl. In certain embodiments, one or more of R^5a, R^5aâ€², R^7aand R^7aâ€² is a [Image Omitted] Z group. In some embodiments, R^5aand R^5aâ€² are a Z group.

In certain embodiments of provided metal complexes, a

[Image Omitted]

moiety has a structure selected from the group consisting of:

[Image Omitted]

In certain embodiments of complexes having formulae described above, at least one of the phenyl rings comprising a salicylaldehyde-derived portion of a catalyst is independently selected from the group consisting of:

[Image Omitted]

where [Image Omitted] (Z)_mrepresents one or more independently-defined activating moieties which may be bonded to any one or more unsubstituted positions of a salicylaldehyde-derived phenyl ring.

In certain embodiments, there is an activating moiety tethered to the position ortho to a metal-bound oxygen substituent of one or both of the salicylaldehyde-derived phenyl rings of a salen ligand as in formulae IIIa and IIIb:

[Image Omitted]

wherein:

- M, X, k, Râ€²,

[Image Omitted]

and [Image Omitted] (Z)_mare as defined above, and

- R^4a, R^4aâ€², R^5a, R^5aâ€², R^6a, and R^6aâ€² are each independently a Z group, hydrogen, halogen, â€”OR, â€”NR₂, â€”SR, â€”CN, â€”NO₂, â€”SO₂R, â€”SOR, â€”SO₂NR₂; â€”CNO, â€”NRSO₂R, â€”NCO, â€”N₃, â€”SiR₃; or an optionally substituted radical selected from the group consisting of C_1-20aliphatic; C_1-20heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- wherein any two adjacent R^4a, R^4aâ€², R^5a, R^5aâ€², R^6a, and R^6aâ€² groups can be taken together with intervening atoms to form one or more optionally substituted rings.

In certain embodiments of compounds having formulae IIIa or IIIb, R^4a, R^4aâ€², R^6a, and R^6aâ€² are each hydrogen, and R^5a, R^5aâ€² are, independently, optionally substituted C₁-C₂₀aliphatic.

In certain embodiments of complexes IIIa and IIIb, at least one of the phenyl rings comprising a salicylaldehyde-derived portion of a catalyst is independently selected from the group consisting of:

[Image Omitted]

In certain embodiments, there is an activating moiety tethered to the position para to the phenolic oxygen of one or both of a salicylaldehyde-derived phenyl rings of the salen ligand as in structures IVa and IVb:

[Image Omitted]

where M, X, k, Râ€², R^4a, R^4aâ€², R^6a, R^6aâ€², R^7a, R^7aâ€²,

[Image Omitted]

and

[Image Omitted] (Z)_mare as defined above.

In certain embodiments of compounds having formulae IVa or IVb, R^4a, R^4aâ€², R^6a, and R^6aâ€² are hydrogen, and each R^7a, R^7aâ€² is, independently, optionally substituted C₁-C₂₀aliphatic.

In certain embodiments of catalysts IVa and IVb, at least one of the phenyl rings comprising a salicylaldehyde-derived portion of a catalyst is independently selected from the group consisting of:

[Image Omitted]

In some embodiments, there is an activating moiety tethered to the position para to the imine substituent of one or both of the salicylaldehyde-derived phenyl rings of a salen ligand as in formulae Va or Vb:

[Image Omitted]

where M, X, k, Râ€², R^4a, R^4aâ€², R^5a, R^5aâ€², R^7a, R^7aâ€²,

[Image Omitted]

and [Image Omitted] (Z)_mare as defined above.

In certain embodiments of compounds having formulae Va or Vb, each R⁴and R^4ais hydrogen, and each R^5a, R^5aâ€², R^7a, R^7aâ€² is, independently, hydrogen or optionally substituted C₁-C₂₀aliphatic.

In certain embodiments of catalysts Va and Vb, at least one of the phenyl rings comprising a salicylaldehyde-derived portion of a catalyst is independently selected from the group consisting of:

[Image Omitted]

In some embodiments, there is an activating moiety tethered to the position ortho to the imine substituent of one or both of the salicylaldehyde-derived phenyl rings of a salen ligand as in formulae VIa and VIb:

[Image Omitted]

where X, k, M, Râ€², R^5a, R^5aâ€², R^6a, R^6aâ€², R^7a, R^7aâ€²,

[Image Omitted]

and [Image Omitted] (Z)_mare as defined above.

In certain embodiments of compounds having formulae VIa or VIb, each R^6aand R^6aâ€² is hydrogen, and each R^5a, R^5aâ€², R^7a, and R^7aâ€² is, independently, hydrogen or optionally substituted C₁-C₂₀aliphatic.

In certain embodiments of catalysts VIa and VIb, at least one of the phenyl rings comprising a salicylaldehyde-derived portion of a catalyst is independently selected from the group consisting of:

[Image Omitted]

In some embodiments, there are activating moieties tethered to the positions ortho and para to the phenolic oxygen of one or both of the salicylaldehyde-derived phenyl rings of a salen ligand as in formulae VIIa and VIIb:

[Image Omitted]

where M, X, k, Râ€², R^4a, R^4aâ€², R^6a, R^6aâ€²,

[Image Omitted]

and [Image Omitted] (Z)_mare as defined above.

In certain embodiments of compounds having formulae VIa or VIb, each R^6a, R^6aâ€², R^4a, and R^4aâ€² is, independently, hydrogen or optionally substituted C₁-C₂₀aliphatic.

In certain embodiments of compounds having formulae VIIa or VIIb, each R^6a, R^6aâ€², R^4a, and R^4aâ€² is hydrogen.

In some embodiments, there are activating moieties tethered to the positions ortho and para to the imine substituent of one or both of the salicylaldehyde-derived phenyl rings of a salen ligand as in formulae VIIIa and VIIIb:

[Image Omitted]

where X, k, M, Râ€², R^5a, R^5aâ€², R^7a, R^7aâ€²,

[Image Omitted]

and [Image Omitted] (Z)_mare as defined above.

In certain embodiments of compounds having formulae VIIIa or VIIIb, each R^5a, R^5aâ€², R^7a, and R^7aâ€² is, independently, optionally, hydrogen or substituted C₁-C₂₀aliphatic.

In certain embodiments of the present invention, catalysts of structures VIIIa or VIIIb above, at least one of the phenyl rings comprising the salicylaldehyde-derived portion of a catalyst is independently selected from the group consisting of:

[Image Omitted]

In some embodiments, there is an activating moiety tethered to the imine carbon of a salen ligand as in formulae IXa and IXb:

[Image Omitted]

where M, X, k, R^4a, R^4aâ€², R^5a, R^5aâ€², R^6a, R^6aâ€², R^7a, R^7aâ€²,

[Image Omitted]

and [Image Omitted] (Z)_mare as defined above with the proviso that the atom of the activating moiety attached to the salen ligand is a carbon atom.

In certain embodiments of compounds having formulae IXa or IXb, each R^4a, R^4aâ€², R^6a, and R^6aâ€² is hydrogen, and each R^5a, R^5aâ€², R^7a, and R^7aâ€² is, independently, hydrogen or optionally substituted C₁-C₂₀aliphatic.

In certain embodiments of the present invention, metal complexes of structures IXa or IXb above, at least one of the phenyl rings comprising a salicylaldehyde-derived portion of a catalyst is independently selected from the group consisting of:

[Image Omitted]

As shown above, the two phenyl rings derived from salicylaldehyde in the core salen structures need not be the same. Though not explicitly shown in formulae Ia through IXb above, it is to be understood that a catalyst may have an activating moiety attached to different positions on each of the two rings, and such compounds are specifically encompassed within the scope of the present invention. Furthermore, activating moieties can be present on multiple parts of the ligand, for instance activating moieties can be present on the diamine bridge and on one or both phenyl rings in the same catalyst.

In certain embodiments, the salen ligand cores of catalysts Ia through IXb above are selected from the group shown below wherein any available position may be independently substituted with one or more R-groups or one or more activating moieties as described above.

[Image Omitted]

where M, X, and k, are as defined above.

In some embodiments, at least one activating moiety is tethered to the diamine-derived portion of the salen ligand, as shown in formula X:

[Image Omitted]

where M, X, k, Râ€²,

[Image Omitted]

and [Image Omitted] (Z)_mare as defined above.

In certain embodiments, salen ligands of formula X are selected from an optionally substituted moiety consisting of:

[Image Omitted]

where M, X, k, Râ€², and [Image Omitted] (Z)_mare as defined above.

In certain embodiments, the diamine bridge of catalysts of formula Xa an optionally substituted moiety selected from the group consisting of:

[Image Omitted]

where M and [Image Omitted] (Z)_mis as defined above.

In certain embodiments, metallosalenate complexes of the present invention include, but are not limited to those in Table 1 below:

TABLE 1

In certain embodiments, for complexes of Table 1, M is Coâ€”X, where X is as defined above. In certain embodiments, for complexes of Table 1, M is Coâ€”OC(O)CF₃. In certain embodiments, for complexes of Table 1, M is Coâ€”OAc. In certain embodiments, for complexes of Table 1, M is Coâ€”OC(O)C₆F₅. In certain embodiments, for complexes of Table 1, M is Coâ€”N₃. In certain embodiments, for complexes of Table 1, M is Coâ€”Cl. In certain embodiments, for complexes of Table 1, M is Co-nitrophenoxy. In certain embodiments, for complexes of Table 1, M is Co-dinitrophenoxy.

In some embodiments, for complexes of Table 1, M is Crâ€”X, where X is as defined above.

In certain embodiments, a tetradentate ligand is a porphyrin ligand. In some embodiments, a metal complex is a cobalt porphyrin complex. In certain embodiments, a metal complex is a chromium porphyrin complex. In some embodiments, a metal complex is an aluminum porphyrin complex.

Examples of porphyrin containing metal complexes of the present invention include, but are not limited to:

[Image Omitted]

wherein each of M, X, k, Râ€², and [Image Omitted] (Z)_mis as defined above.

In certain embodiments, a multidentate ligand is an optionally substituted tetrabenzoporphyrin. Suitable examples include, but are not limited to:

[Image Omitted]

wherein M, Râ€², and [Image Omitted] (Z)_nare as previously defined.

In certain embodiments of porphyrin and phthalocyanine-based complexes described herein, M is aluminum. In certain embodiments of porphyrin and phthalocyanine-based complexes described herein, M is cobalt. In certain embodiments of porphyrin and phthalocyanine-based complexes described herein, M is manganese.

In certain embodiments, porphyrin complexes of the present invention include, but are not limited to those in Table 2 below:

TABLE 2

In certain embodiments, for complexes of Table 2, M is Coâ€”X, where X is as defined above. In certain embodiments, for complexes of Table 2, M is Coâ€”OC(O)CF₃. In certain embodiments, for complexes of Table 2, M is Coâ€”OAc. In certain embodiments, for complexes of Table 1, M is Coâ€”OC(O)C₆F₅. In certain embodiments, for complexes of Table 2, M is Coâ€”N₃. In certain embodiments, for complexes of Table 2, M is Coâ€”Cl. In certain embodiments, for complexes of Table 2, M is Co-nitrophenoxy. In certain embodiments, for complexes of Table 2, M is Co-dinitrophenoxy.

In certain embodiments, for complexes of Table 2, M is Alâ€”X, where X is as defined above. In certain embodiments, for complexes of Table 2, M is Crâ€”X, where X is as defined above.

In certain embodiments, porphyrin complexes of the present invention are synthesized as shown in the following schemes:

[Image Omitted]

In some embodiments, the present disclosure provides methods of polymerization comprising contacting an epoxide with carbon dioxide in the presence of a provided metal complex to form a polycarbonate. In some embodiments, the present invention provides a method of polymerization, the method comprising:

- a) providing an epoxide of formula:

[Image Omitted]

- - wherein:
  - R^aâ€²is hydrogen or an optionally substituted radical selected from the group consisting of C_1-30aliphatic; C_1-30heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and
  - each of R^bâ€², R^câ€², and R^dâ€² is independently hydrogen or an optionally substituted radical selected from the group consisting of C_1-12aliphatic; C_1-12heteroaliphatic; phenyl; a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, a 7-14 carbon saturated, partially unsaturated or aromatic polycyclic carbocycle; a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 6- to 12-membered polycyclic saturated or partially unsaturated heterocycle having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  - wherein any of (R^aâ€² and R^câ€²), (R^câ€² and R^dâ€²), and (R^aâ€²and R^bâ€²) can be taken together with intervening atoms to form one or more optionally substituted rings;
- b) contacting the epoxide and carbon dioxide in the presence of a metal complex as described herein to provide a polymer having a formula selected from the group consisting of:

[Image Omitted]

In some embodiments, a provided polymer has a formula:

[Image Omitted]

In some embodiments, a provided polymer has a formula:

[Image Omitted]

In some embodiments, carbon dioxide is optional and a provided polymer has a formula:

[Image Omitted]

In certain embodiments, R^bâ€², R^câ€², and R^dâ€² are each hydrogen. In some embodiments, R^aâ€² is optionally substituted C_1-12aliphatic. In some embodiments, R^aâ€² is optionally substituted C_1-12heteroaliphatic. In some embodiments, the epoxide is ethylene oxide, propylene oxide, or cyclohexene oxide.

In certain embodiments, one of R^aâ€², R^bâ€², R^câ€², and R^dâ€² is hydrogen. In certain embodiments, two of R^aâ€², R^bâ€², R^câ€², and R^dâ€² are hydrogen. In certain embodiments, three of R^aâ€², R^bâ€², R^câ€², and R^dâ€² are hydrogen.

In certain embodiments, R^aâ€²is hydrogen. In certain embodiments, R^bâ€² is hydrogen. In certain embodiments, R^câ€² is hydrogen. In certain embodiments, R^dâ€² is hydrogen.

In certain embodiments, R^aâ€², R^bâ€², R^câ€², and R^dâ€² are each independently an optionally substituted C_1-30aliphatic group. In certain embodiments, R^aâ€², R^bâ€², R^câ€², and R^dâ€² are each independently an optionally substituted C_1-20aliphatic group. In certain embodiments, R^aâ€², R^bâ€², R^câ€², and R^dâ€² are each independently an optionally substituted C_1-12aliphatic group. In certain embodiments, R^aâ€², R^bâ€², R^câ€², and R^dâ€² are each independently an optionally substituted C_1-8aliphatic group. In certain embodiments, R^aâ€², R^bâ€², R^câ€², and R^dâ€² are each independently an optionally substituted C_3-8aliphatic group. In certain embodiments, R^aâ€², R^bâ€², R^câ€², and R^dâ€² are each independently an optionally substituted C_3-12aliphatic group.

In certain embodiments, R^aâ€² is an optionally substituted C_1-30aliphatic group. In certain embodiments, R^bâ€² is an optionally substituted C_1-30aliphatic group. In certain embodiments, R^câ€² is an optionally substituted C_1-30aliphatic group. In certain embodiments, R^dâ€² is an optionally substituted C_1-30aliphatic group.

In some embodiments, an R^aâ€² and an R^bâ€² attached to the same carbon are taken together to form one or more optionally substituted 3-12-membered carbocyclic rings. In some embodiments, an R^aâ€² and an R^bâ€² attached to the same carbon are taken together to form a polycyclic carbocycle comprising two or more optionally substituted 3-8-membered carbocyclic rings. In some embodiments, an R^aâ€² and an R^bâ€² attached to the same carbon are taken together to form a polycyclic carbocycle comprising two or more optionally substituted 5-7-membered carbocyclic rings.

In some embodiments, an R^aâ€²and an R^bâ€² attached to the same carbon are taken together to form a bicyclic carbocycle comprising two optionally substituted 3-12-membered carbocyclic rings. In some embodiments, an R^aâ€² and an R^bâ€² attached to the same carbon are taken together to form a bicyclic carbocycle comprising two optionally substituted 3-8-membered carbocyclic rings. In some embodiments, an R^aâ€² and an R^bâ€² attached to the same carbon are taken together to form a bicyclic carbocycle comprising two optionally substituted 5-7-membered carbocyclic rings.

In certain embodiments, an R^aâ€²and an R^bâ€² attached to the same carbon are taken together to form an optionally substituted 3-12-membered carbocyclic ring. In certain embodiments, an R^aâ€²and an R^bâ€² attached to the same carbon are taken together to form an optionally substituted 3-8-membered carbocyclic ring. In certain embodiments, an R^aâ€² and an R^bâ€² attached to the same carbon are taken together to form an optionally substituted 5-7-membered carbocyclic ring.

In some embodiments, an R^bâ€² and an R^câ€² attached to adjacent carbons are taken together to form one or more optionally substituted 3-12-membered carbocyclic rings. In some embodiments, an R^bâ€² and an R^câ€² attached to adjacent carbons are taken together to form a polycyclic carbocycle comprising two or more optionally substituted 3-8-membered carbocyclic rings. In some embodiments, an R^bâ€² and an R^câ€² attached to adjacent carbons are taken together to form a polycyclic carbocycle comprising two or more optionally substituted 5-7-membered carbocyclic rings.

In some embodiments, an R^bâ€² and an R^câ€² attached to adjacent carbons are taken together to form a bicyclic carbocycle comprising two optionally substituted 3-12-membered carbocyclic rings. In some embodiments, an R^bâ€² and an R^câ€² attached to adjacent carbons are taken together to form a bicyclic carbocycle comprising two optionally substituted 3-8-membered carbocyclic rings. In some embodiments, an R^bâ€² and an R^câ€² attached to adjacent carbons are taken together to form a bicyclic carbocycle comprising two optionally substituted 5-7-membered carbocyclic rings.

In certain embodiments, an R^bâ€² and an R^câ€² attached to adjacent carbons are taken together to form an optionally substituted 3-12-membered carbocyclic ring. In certain embodiments, an R^bâ€² and an R^câ€² attached to adjacent carbons are taken together to form an optionally substituted 3-8-membered carbocyclic ring. In certain embodiments, an R^bâ€² and an R^câ€² attached to adjacent carbons are taken together to form an optionally substituted 5-7-membered carbocyclic ring.

In certain embodiments, the polymer comprises a copolymer of two different repeating units where R^aâ€², R^bâ€², and R^câ€² of the two different repeating units are not all the same. In some embodiments, a polymer comprises a copolymer of three or more different repeating units wherein R^aâ€², R^bâ€², and R^câ€² of each of the different repeating units are not all the same as R^aâ€², R^bâ€², and R^câ€² of any of the other different repeating units. In some embodiments, a polymer is a random copolymer. In some embodiments, a polymer is a tapered copolymer.

In some embodiments, a polymer contains a metal complex as described herein. In some embodiments, a polymer comprises residue of a metal complex as described herein. In some embodiments, a polymer comprises a salt of an organic cation and X, wherein X is a nucleophile or counterion. In some embodiments, X is 2,4-dinitrophenolate anion.

In some embodiments, R^aâ€² is optionally substituted C_1-12aliphatic. In some embodiments, R^aâ€² is optionally substituted C_1-12heteroaliphatic. In some embodiments, R^aâ€² is optionally substituted phenyl. In some embodiments, R^aâ€² is optionally substituted 8- to 10-membered aryl. In some embodiments, R^aâ€² is optionally substituted 5- to 10-membered heteroaryl. In some embodiments, R^aâ€² is optionally substituted 3- to 7-membered heterocyclic.

In certain embodiments, R^aâ€² is selected from methyl, ethyl, propyl, butyl, vinyl, allyl, phenyl, trifluoromethyl,

[Image Omitted]

or any two or more of the above. In certain embodiments, R^aâ€² is methyl. In certain embodiments, R^aâ€² is ethyl. In certain embodiments, R^aâ€² is propyl. In certain embodiments, R^aâ€² is butyl. In certain embodiments, R^aâ€² is vinyl. In certain embodiments, R^aâ€² is allyl. In certain embodiments, R^aâ€² is phenyl. In certain embodiments, R^aâ€² is trifluoromethyl. In certain embodiments, R^aâ€² is

[Image Omitted]

In certain embodiments, R^aâ€² is

[Image Omitted]

In certain embodiments, R^aâ€²is

[Image Omitted]

In certain embodiments, R^aâ€² is

[Image Omitted]

In certain embodiments, R^aâ€² is

[Image Omitted]

In certain embodiments, R^aâ€² is

[Image Omitted]

In certain embodiments, R^aâ€² is

[Image Omitted]

In some embodiments, R^bâ€² is hydrogen. In some embodiments, R^bâ€² is optionally substituted C_1-12aliphatic. In some embodiments, R^bâ€² is optionally substituted C_1-12heteroaliphatic. In some embodiments, R^bâ€² is optionally substituted phenyl. In some embodiments, R^bâ€² is optionally substituted 8- to 10-membered aryl. In some embodiments, R^bâ€² is optionally substituted 5- to 10-membered heteroaryl. In some embodiments, R^bâ€² is optionally substituted 3- to 7-membered heterocyclic.

In some embodiments, R^câ€² is hydrogen. In some embodiments, R^câ€² is optionally substituted C_1-12aliphatic. In some embodiments, R^câ€² is optionally substituted C_1-12heteroaliphatic. In some embodiments, R^câ€² is optionally substituted phenyl. In some embodiments, R^câ€² is optionally substituted 8- to 10-membered aryl. In some embodiments, R^câ€² is optionally substituted 5- to 10-membered heteroaryl. In some embodiments, R^câ€² is optionally substituted 3- to 7-membered heterocyclic.

In some embodiments, R^aâ€² and R^câ€² are taken together with intervening atoms to form one or more rings selected from the group consisting of: optionally substituted C₃-C₁₄carbocycle, optionally substituted 3- to 14-membered heterocycle, optionally substituted phenyl, optionally substituted C₈-C₁₀aryl, and optionally substituted 5- to 10-membered heteroaryl.

In some embodiments, R^bâ€² and R^câ€² are taken together with intervening atoms to form one or more rings selected from the group consisting of: optionally substituted C₃-C₁₄carbocycle, optionally substituted 3- to 14-membered heterocycle, optionally substituted phenyl, optionally substituted C₈-C₁₀aryl, and optionally substituted 5- to 10-membered heteroaryl.

In some embodiments, R^aâ€² and R^bâ€² are taken together with intervening atoms to form one or more rings selected from the group consisting of: optionally substituted C₃-C₁₄carbocycle, optionally substituted 3- to 14-membered heterocycle, optionally substituted phenyl, optionally substituted C₈-C₁₀aryl, and optionally substituted 5- to 10-membered heteroaryl.

In some embodiments, the invention includes methods for synthesizing polyethers from epoxides. Suitable methods of performing these reactions are disclosed in U.S. Pat. No. 7,399,822, the entire contents of which are hereby incorporated herein by reference.

In some embodiments, the invention includes methods for synthesizing cyclic carbonates from carbon dioxide and epoxides using catalysts described above, suitable methods of performing this reaction are disclosed in U.S. Pat. No. 6,870,004 which is incorporated herein by reference.

EXAMPLESExample 1

A general route to a symmetric cobalt (III) salen ligand of the present invention is shown in Schemes E1 and E2, below:

[Image Omitted]

As shown in Scheme E1, disubstituted phenol E1-a is formylated to provide salicylaldehyde derivative E1-b. Two equivalents of this aldehyde are then reacted with a diamine (in this case 1,2-diamino cyclohexane) to afford Schiff base E1-c. This compound is then reacted with cobalt (II) acetate to give the Co(II)-salen complex (not shown) which is oxidized by air in the presence of trifluoroacetic acid to afford the active cobalt (III) catalyst. Similar chemistries can be applied to synthesis of the catalysts described hereinabove. One skilled in the art of organic synthesis can adapt this chemistry as needed to provide the specific catalysts described herein.

Example 2

A typical route to an asymmetric cobalt (III) salen ligand is shown in Scheme E2:

[Image Omitted]

As shown in Scheme E2, disubstituted salicylaldehyde derivative E1-b is treated with one equivalent of a monohydrochloride salt of 1,2 cyclohexanediamine the resulting Schiff base E2-a is then neutralized and a second different salicylaldehyde derivative is added. This compound is then reacted with cobalt (II) acetate to give the Co(II)-salen complex which is oxidized by air in the presence of trifluoroacetic acid to afford the active cobalt (III) catalyst. Similar chemistries can be applied to synthesis of the catalysts described hereinabove. One skilled in the art of organic synthesis can adapt this chemistry as needed to provide the specific catalysts described herein.

Example 3

Example 3 describes the synthesis of a catalyst

[Image Omitted]

where M is Co(III),

[Image Omitted]

is salcy, [Image Omitted] is

[Image Omitted]

Z is a P-linked phosphorimine moiety

[Image Omitted]

and m is 1, wherein there are one or two [Image Omitted] (Z)_mgroups present (Scheme E4 and E3, respectively).

[Image Omitted]

As shown in Scheme E3, triol E3-a is protected as a ketal to afford monohydric alcohol E3-b, this compound is then alkylated with bromide E3-c to afford benzyl ether E3-d. Deprotection and oxidation of the other benzylic alcohol affords salicylaldehyde E3-e which is condensed with cyclohexanediamine as described above to give ligand E3-f. The phosphorimine nitrogen is then quaternized and the metal complex formed as before to provide catalyst E3-h. In an alternative route not shown here the metal is first inserted and then quarternization is performed.

[Image Omitted]

As shown in Scheme E3b, salicyladedyde E3-e (described above) is condensed with cyclohexanediamine monohydrochloride to afford the mono-Schiff base hydrochloride E4a. This salt is then neutralized, condensed with di-t-butyl salicaldehyde, and methylated to give E4-b. The resulting ligand is metallated and oxidized as described above for Scheme E3 to give catalyst E4-c.

Example 4

Example 4 describes the synthesis of catalysts where M is Co(III),

[Image Omitted]

is salcy, [Image Omitted] is

[Image Omitted]

Z is a 1-[4-dimethylamino-pyridinium]

[Image Omitted]

or 1-[N-methylimidazolium],

[Image Omitted]

and m is 1, wherein there are one or two [Image Omitted] (Z)_mgroups present (Scheme E5 and E6, respectively).

[Image Omitted]

Scheme E4 shows the synthesis of compounds CS-6 and CS-7. For each compound trans-1,2-Diaminocyclohexane (2.0 mol) is slowly added to an anhydrous ethanol solution of benzyl chloride CS-4 (1.0 mol). The reaction is stirred and heated to reflux for 3 h, then cooled to rt and diluted with water. This mixture is cooled overnight in the freezer and solids are collected by filtration to afford dichloride CS-5. The dichloride CS-5 (1.0 mol) is reacted with N,N-Dimethylamino pyridine (2.0 mol) or N-methyl imidazole in acetonitrile. The reactions are heated at 80Â° C. for 18 h and then the solvent is removed in vacuo to provide the respective ammonium salts. These salts are metallated and oxidized as described previously to provide catalysts CS-6 and CS-7.

Example 5

Example 5 describes the synthesis of catalysts where M is Co(III),

[Image Omitted]

is salcy, [Image Omitted] is

[Image Omitted]

Z is a 1-[N-methylimidazolium] (CS-8), or dimethylamino (CS-9) and m is 1, wherein there are two [Image Omitted] (Z)_mgroups present (Scheme E5 and E6, respectively).

[Image Omitted]

Scheme E5 shows the synthesis of compounds CS-8 and CS-9 using conditions similar to those described above. Synthesis of CS-8: The known compound 1-(2-methylaminoethyl)-3-methylimidazole (2.0 mol) is combined with CS-5 (1.0 mol) in acetonitrile. The reaction is heated to 80Â° C. for 18 h and then the solvent is removed in vacuo, metallation with Co(OAc)₂and oxidation in TFA are then performed as described above to afford catalyst CS-8. Synthesis of CS-9: N,N,Nâ€²-Trimethyl-1,2-ethanediamine (4.0 mol) is combined with CS-5 (1.0 mol) in acetonitrile. The reaction is heated to 80Â° C. for 18 h, cooled, and the solvent is removed in vacuo. The crude product is diluted with ether, filtered to remove amine salts, and concentrated in vacuo. The residue is dissolved in degassed methanol and combined with Co(OAc)₂(1.0 mol). After stirring for 3 h the residue is filtered and washed with methanol. Trifluoroacetic acid (1.0 mol) is added slowly to a stirring solution of the solid residue in dichloromethane. After stirring open to air for 3 h, the solids are filtered and dried in vacuo to produce CS-9.

Example 6

Example 6 and Scheme E6 describe the synthesis of catalysts where M is Co(III),

[Image Omitted]

is salcy, [Image Omitted] is

[Image Omitted]

Z is dibutylamino and m is 1, wherein there are two [Image Omitted] (Z)_mgroups present.

[Image Omitted]

Synthesis of CS-10:

Ligand CS-5 (1.0 mol), 3-(dibutylamino)-1-propanol (2.0 mol), a 50% NaOH solution (10 mol), tetrabutylammonium bisulphate (4 mol %), and dichloromethane are combined and heated at 65Â° C. overnight. The reaction mixture is concentrated in vacuo to remove the bulk of the solvent and the aqueous layer is extracted with ethyl acetate. The organic layer is separated, dried with magnesium sulfate, filtered, and concentrated in vacuo. After purification using silica gel the product is dissolved in degassed methanol and combined with Co(OAc)₂(1.0 mol). After stirring for 3 h, the residue is filtered and washed with methanol. Trifluoroacetic acid (1.0 mol) is added slowly to a dichloromethane solution of the solid residue. After stirring open to air for 3 h, the solids are filtered and dried in vacuo to produce CS-10.

Example 7

Example 7 and Scheme E7 describe the synthesis of catalysts where M is Co(III),

[Image Omitted]

is salcy, [Image Omitted] includes two

[Image Omitted]

groups taken together to form a ring including the Z group, Z is 3-[N-methylpyridinium] and m is 1, wherein there is one [Image Omitted] (Z)_mgroup present.

[Image Omitted]

Synthesis of CS-11.

Ligand CS-5 (1.0 mol), 3,5-bis(hydroxymethyl)-N-methylpyridinium iodide (2.0 mol), a 50% NaOH solution (10 mol), tetrabutylammonium bisulphate (4 mol %), and dichloromethane are combined and heated at 65Â° C. overnight. The reaction mixture is concentrated in vacuo to remove the bulk of the solvent and the aqueous layer is extracted with ethyl acetate. The organic layer is separated, dried with magnesium sulfate, filtered, and concentrated in vacuo. The procedure detailed above for the metallation and oxidation is followed to produce CS-11.

Example 8

Example 8 and Scheme E8 describe the synthesis of catalysts where M is Co(III),

[Image Omitted]

is salcy, [Image Omitted] is

[Image Omitted]

Z is 1-[4-t-butylpyridinium], and m is 2, wherein there are two [Image Omitted] (Z)_mgroups present.

[Image Omitted]

Synthesis of AC-2.

Intermediate AC-1 (0.37 g, 0.35 mmol), 4-tbutylpyridine (0.21 mL, 1.41 mmol), and AcCN (4 mL) were combined in a sealed vial and heated to 80Â° C. with stirring for 18 h. The solvent was removed in vacuo, leaving a yellow residue (0.61 g, 110% yield, AcCN present). ¹H NMR (400 MHz, CDCl₃, Î´): 9.53 (t, 8H), 8.21 (s, 2H), 7.94 (t, 8H), 7.08 (s, 2H), 6.83 (s, 2H), 4.81 (m, 8H), 3.29 (m, 2H), 2.78 (m, 2H), 2.15 (s, 6H), 1.5-2.0 (m, 24H), 1.36 (s, 36H); IR (ATR, film cast from AcCN): Î½_{Câ• N}=1637 cm^âˆ’1. A solution of the residue (0.30 g, 0.19 mmol) in dry EtOH (5 mL) was added to AgBF₄(0.19 g, 0.85 mmol) in a schlenk tube and stirred overnight shielded from the light. The solution was filtered through Celite and the solvent was removed in vacuo, giving a solid residue. This residue was flashed over a small plug of silica gel with 5:1 CH₂Cl₂:EtOH as eluant. The solvent was removed to give a solid residue (0.18 g, 67% yield). ¹H NMR (400 MHz, CDCl₃, Î´): 8.75 (t, 8H), 7.98 (d, 2H), 7.92 (t, 8H), 7.1-7.3 (m, 4H), 4.52 (m, 8H), 3.6 (m, 2H), 2.7 (m, 2H), 2.19 (s, 6H), 1.5-2.0 (m, 24H), 1.38 (s, 36H); IR (ATR, film cast from CH₂Cl₂): Î½_{Câ• N}=1641 cm^âˆ’1, Î½_BF4=1050 cm^âˆ’1. A solution of the residue (0.18 g, 0.12 mmol) in dry EtOH (4 mL) was added to Co(OAc)₂(0.022 g, 0.12 mmol) in a schlenk tube under N₂. The solution was stirred for 3 h at room temperature, and the solvent was removed in vacuo. The residue was triturated with ether, dried in vacuo, and redissolved in CH₂Cl₂. A solution of CF₃CO₂H (9 Î¼L, 0.12 mmol) in CH₂Cl₂(80 Î¼L) was added and the solution stirred for 3 h open to air. Solid NaO₂CCF₃(0.067 g, 0.49 mmol) was added, and the solution was stirred under N₂for 2 days. The solution was filtered through Celite and the solvent was removed in vacuo to leave a brown residue (0.071 g, 37% yield). ¹H NMR (400 MHz, DMSO-d₆, Î´): 8.86 (t, 8H), 8.08 (t, 8H), 8.07 (s, 2H), 7.30 (m, 4H), 4.44 (m, 8H), 3.54 (m, 2H), 2.9 (m, 2H), 2.47 (s, 6H), 1.5-2.0 (m, 24H), 1.29 (s, 36H); IR (ATR): Î½_{Câ• O}=1682 cm^âˆ’1, Î½_{Câ• N}=1641 cm^âˆ’1.

Additional ligands AC-6 through AC-11 were synthesized using the conditions described for compound AC-2 and are summarized in Scheme E8b and Table E8:

[Image Omitted]

TABLE E8Com-QIR^bpound(Scheme E8b)¹H NMR spectra^a(Î´, ppm)(cm^âˆ’1)AC-6^c [Image Omitted]

9.0 (d, 8H), 8.6 (t, 4H), 8.5 (s, 2H), 8.1 (t, 8H), 6.9 (s, 2H), 6.8 (s, 2H), 4.5 (t, 8H), 3.4 (m, 2H), 2.1 (s, 6H), 1.4-2.9 (m, 24H).v_{Câ• N} = 1629 AC-7 [Image Omitted]

8.61 (d, 8H), 8.29 (s, 2H), 6.99 (s, 2H), 6.92 (d, 8H), 6.85 (s, 2H), 4.30 (t, 8H), 3.34 (m, 2H), 3.23 (s, 24H), 2.65 (m, 2H), 2.18 (s, 6H), 1.4-2.9 (m, 16H).v_{Câ• N} = 1649 AC-8 [Image Omitted]

v_{Câ• N} = 1627 AC-9 [Image Omitted]

v_{Câ• N} = 1610 AC-10 [Image Omitted]

v_{Câ• N} = 1627 AC-11 [Image Omitted]

v_{Câ• N} = 1628^a400 MHz, CDCl₃.^bAll compounds exhibited the loss of a peak at 1213 cm^âˆ’1 attributed to the CH₂I group in AC-1.^cNMR spectrum is in DMSO-d₆.

Example 9

Example 9 and Scheme E9 describe the synthesis of catalysts where M is Co(III),

[Image Omitted]

is salcy, [Image Omitted] is

[Image Omitted]

Z is N,N-bis-(3-dimethylaminopropyl)amino (AC-4), tetramethyl guanidino (AC-5), N-linked morpholino (AC-6), or N-linked piperidino (AC-14), and m is 2, wherein there are two [Image Omitted] (Z)_mgroups present.

[Image Omitted]

Synthesis of AC-4.

Intermediate AC-3 (0.45 g, 0.63 mmol), 3,3â€²-iminobis(N,Nâ€²-dimethylpropylamine) (0.28 mL, 1.26 mmol), K₂CO₃(0.35 g, 2.52 mmol) and AcCN (5 mL) were combined in a sealed vial and heated to 80Â° C. with stirring for 18 h. The solution was filtered and the solvent was removed in vacuo, triturated with ether, and dried in vacuo to leave a yellow residue (0.48 g, 91% yield). ¹H NMR (400 MHz, CDCl₃, Î´): 8.21 (m, 2H), 6.8-7.2 (m, 4H), 3.75 (m, 2H), 3.0-3.4 (m, 20H), 2.0-2.8 (m, 28H), 2.18 (s, 6H), 1.4-2.0 (m, 24H); IR (ATR): Î½_{Câ• N}=1600 cm^âˆ’1. A solution of the residue (0.21 g, 0.25 mmol) in dry EtOH (10 mL) was added to Co(OAc)₂(0.045 g, 0.25 mmol) in a schlenk tube under N₂. CH₂Cl₂(3 mL) was added to completely dissolve the solution. The solution was stirred for 18 h at room temperature, and the solvent was removed in vacuo. The residue was triturated with ether, dried in vacuo, and redissolved in CH₂Cl₂(10 mL). CF₃CO₂H (20 Î¼L, 0.25 mmol) was added and the solution stirred for 3.5 h open to air. The solvent was removed in vacuo, triturated with ether, and dried in vacuo to leave a brown residue (0.28 g, 108% yield, residual CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, Î´): 7.92 (m, 2H), 7.1-7.4 (m, 4H), 3.58 (m, 2H), 3.0-3.4 (m, 20H), 2.0-2.8 (m, 28H), 2.3 (s, 6H), 1.4-2.0 (m, 24H); IR (ATR): Î½_{Câ• O}=1688 cm^âˆ’1, Î½_{Câ• N}=1616 cm^âˆ’1.

Synthesis of AC-5.

Intermediate AC-3 (0.20 g, 0.29 mmol), 1,1,3,3-tetramethylguanidine (0.21 mL, 1.71 mmol), K₂CO₃(0.39 g, 2.85 mmol) and AcCN (2 mL) were combined in a sealed vial and reacted as in AC-4, except that the residue was also washed with hexanes. ¹H NMR (400 MHz, CDCl₃, Î´): 8.23 (d, 2H), 6.95 (s, 2H), 6.80 (s, 2H), 3.35 (m, 2H), 3.1 (m, 4H), 2.7-2.8 (m, 24H), 2.48 (m, 4H), 2.20 (s, 6H), 1.4-2.0 (m, 16H); IR (ATR): Î½_{Câ• N}=1594 cm^âˆ’1. The residue was reacted as in AC-4. IR (ATR): Î½_{Câ• O}=1690 cm^âˆ’1, Î½_{Câ• N}=1610 cm^âˆ’1.

Synthesis of AC-6.

Intermediate AC-3 (0.32 g, 0.44 mmol), morpholine (0.16 mL, 1.77 mmol), K₂CO₃(0.61 g, 4.4 mmol) and AcCN (4 mL) were combined in a sealed vial and reacted as in AC-4, except that the residue was also washed with a NaOAc buffer (pH=4) solution to remove residual morpholine. ¹H NMR (400 MHz, CDCl₃, Î´): 8.22 (s, 2H), 6.92 (s, 2H), 6.79 (s, 2H), 3.69 (m, 8H), 3.28 (m, 2H), 2.2-2.5 (m, 16H), 2.19 (s, 6H), 1.4-2.0 (m, 16H). The residue was reacted as in AC-4. ¹H NMR (400 MHz, DMSO-d₆, Î´): 7.91 (s, 2H), 7.23 (s, 2H), 7.14 (s, 2H), 3.6 (m, 2H), 3.52 (m, 8H), 2.99 (m, 2H), 2.57 (s, 6H), 2.47 (m, 4H), 2.2-2.5 (m, 12H), 1.4-2.0 (m, 16H); IR (ATR): Î½_{Câ• O}=1671 cm^âˆ’1, Î½_{Câ• N}=1630 cm^âˆ’1.

Additional ligands AC-13 and AC-14 were synthesized using the conditions described for compounds AC-4 through AC-6 and are summarized in Scheme E9b and Table E9:

[Image Omitted]

TABLE E9QCompound(Scheme E9b)¹H NMR spectra^a(Î´, ppm)IR^b(cm^âˆ’1)AC-13 [Image Omitted]

8.25 (s, 2H), 7.02 (d, 2H), 6.77 (d, 2H), 3.7 (m, 8H), 3.3 (m, 2H), 2.2-2.6 (m, 12H), 1.3-2.0 (m, 20H), 1.37 (s, 18H)v_{Câ• N} = 1628 AC-14 [Image Omitted]

v_{Câ• N} = 1629^a400 MHz, CDCl₃.^bAll compounds exhibited the loss of a peak at 1213 cm^âˆ’1 attributed to the CH₂I group in AC-1.

Example 10

Confirmation of inventive concepts, processes, methods, and compositions described herein has been provided, among other ways, through publication by others after the priority date of the present case. For example, Examples 10-27 describe working Examples presented in Chinese Patent Application No. 200810229276.1, published as CN 101412809A. Additional experimental and characterization data are described by Lu and co-workers, J. Am. Chem. Soc., 2009, 131, 11509-11518, and supporting information available at www.pubs.acs.org, the entirety each of which is hereby incorporated by reference.

In certain embodiments, provided catalysts and/or methods for the preparation of polycarbonate are characterized by one or more of the following: retaining high catalytic activity at low catalyst concentration; reaction conditions that are relatively mild; high catalytic activity with high selectivity for polymer product; alternate structure in the polycarbonate product higher than 97% with relatively narrow distribution of molecular weight; retaining high catalytic activity for copolymerization of carbon dioxide and epoxides at higher reaction temperatures (e.g., above 50Â° C., above 75Â° C., or above 100Â° C.); and catalysts that can be used to catalyze the polymerization of carbon dioxide with two or more alkylene oxides for the synthesis of polycarbonate polymer.

The following materials were added sequentially into a stainless steel high pressure reactor of effective volume of 200 mL at ambient temperature: 0.1 mmole of cobalt complex I-a (R₁is cyclohexyl diamine, X is NO₃^âˆ’1anion; R₂â• H; R₃, R₄and R₅are tertiary butyl; group containing organic base group is at position 3 of the benzene ring in the ligand, n is 2) and one mole of propylene oxide. The reactor was then filled with carbon dioxide and the pressure is maintained constant at 2.0 MPa. The temperature was controlled at 25Â° C. The content was stirred with a magnetic stirring bar for 6 hours and the remaining carbon dioxide was slowly released. The remaining alkylene oxide was collected in âˆ’20Â° C. cold trap and a certain amount of mixture of methanol/chloroform was added to dissolve the high polymer. Then a large amount of diethyl ether was added to precipitate the polycarbonate. The precipitate was filtered and washed several times with diethyl ether and dried in vacuum to constant weight to afford 27 grams of polycarbonate as a white solid. The average molecular weight of the polymer was determined by gel permeation chromatography to be 101,000 g/mol with a molecular weight distribution of 1.24. A Varian INOVA-400 MHz Nuclear Magnetic Resonance spectrometer was used to determine its ¹H-NMR and the result showed that the alternate structure is over 99%.

[Image Omitted]

Example 11

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the molar ratio of catalyst to propylene oxide was changed from 1:10000 to 1:50000 (0.02 mmole of catalyst and 1 mole of propylene oxide were used). The reaction was carried out at 25Â° C. for 24 hours to afford 21 grams of poly(propylene carbonate) with a molecular weight of 223,000 g/mol and a molecular weight distribution of 1.29. The polymer formed contained more than 99% carbonate linkages.

Example 12

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the molar ratio of catalyst to propylene oxide was changed from 1:10000 to 1:200000 (0.008 mmole of catalyst and 1.6 mole of propylene oxide were used). The reaction was carried out at 50Â° C. for 10 hours to afford 19 grams of poly(propylene carbonate) with a molecular weight of 318,000 g/mol and a molecular weight distribution of 1.37. The polymer formed contained more than 99% carbonate linkages.

Example 13

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the molar ratio of catalyst to propylene oxide was changed from 1:10000 to 1:2000 (0 5 mmole of catalyst and 1 mole of propylene oxide were used). The reaction was carried out at 25Â° C. for 3 hours to afford 48 grams of poly(propylene carbonate) with a molecular weight of 52,800 g/mol and a molecular weight distribution of 1.30. The polymer formed contained more than 99% carbonate linkages.

Example 14

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the reaction temperature was changed from 25Â° C. to 100Â° C. and the reaction was carried out for 0.5 hours to afford 34 grams of poly(propylene carbonate) with a molecular weight of 112,400 g/mol and a molecular weight distribution of 1.38. The polymer formed contained more than 99% carbonate linkages.

Example 15

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the reaction temperature was changed from 25Â° C. to 10Â° C. and the reaction was carried out for 10 hours to afford 18 grams of poly(propylene carbonate) with a molecular weight of 914,000 g/mol and a molecular weight distribution of 1.38. The polymer formed contained more than 99% carbonate linkages.

Example 16

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the propylene oxide was replaced with 1,2-butylene oxide. The reaction was carried out at 25Â° C. for 6 hours to afford 31 grams of poly(butylene carbonate) with a molecular weight of 127,000 g/mol and a molecular weight distribution of 1.21. The polymer formed contained more than 99% carbonate linkages.

Example 17

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the propylene oxide was replaced with 1,2-octylene oxide. The reaction was carried out at 25Â° C. for 10 hours to afford 34 grams of poly(octylene carbonate) with a molecular weight of 109,000 g/mol and a molecular weight distribution of 1.38. The polymer formed contained more than 99% carbonate linkages.

Example 18

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the propylene oxide was replaced with a mixture of propylene oxide and cyclohexylene oxide (the molar ratio of the catalyst to propylene oxide and cyclohexylene oxide was 1:5000:5000). The reaction was carried out at 50Â° C. for 6 hours to afford 59 grams of poly(propylene-co-cyclohexene carbonate) with a molecular weight of 187,000 g/mol and a molecular weight distribution of 1.29. The polymer formed contained more than 99% carbonate linkages.

Example 19

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the axial anion in the cobalt complex I-a was changed from nitrate radical to acetate moiety. The reaction was carried out at 25Â° C. for 6 hours to afford 34 grams of poly(propylene carbonate) with a molecular weight of 95,000 g/mol and a molecular weight distribution of 1.28. The polymer formed contained more than 99% carbonate linkages.

Example 20

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the diamine skeleton in the cobalt complex I-a was changed from cyclohexane diamine to ethylene diamine The reaction was carried out at 25Â° C. for 6 hours to afford 29 grams of poly(propylene carbonate) with a molecular weight of 112,000 g/mol and a molecular weight distribution of 1.20. The polymer formed contained more than 99% carbonate linkages.

Example 21

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the diamine skeleton in the cobalt complex I-a was changed from cyclohexane diamine to o-phenylene diamine The reaction was carried out at 25Â° C. for 6 hours to afford 25 grams of poly (propylene carbonate) with a molecular weight of 92,000 g/mol and a molecular weight distribution of 1.15. The polymer formed contained more than 99% carbonate linkages.

Example 22

The following materials were added sequentially into a stainless steel high pressure reactor of volume of 200 mL at ambient temperature: 0.1 mmole of cobalt complex I-b (R₁is 1,2-propylene diamine, X is dinitrophenyl anion; R₂â• H; R₁is tertiary butyl; there are organic base groups at position 5 of the two benzene rings in the ligand, n is 0) and 1 mole of propylene oxide. The reactor was then filled with carbon dioxide and the pressure was maintained constant at 2.0 MPa. The reaction was carried out at 25Â° C. for 6 hours to afford 23 grams of polycarbonate as a white solid. The average molecular weight of the polymer was determined by gel permeation chromatography to be 81,000 g/mol with a molecular weight distribution of 1.34. The polymer formed contained more than 99% carbonate linkages.

[Image Omitted]

Example 23

The following materials were added sequentially into a stainless steel high pressure reactor of volume of 200 mL at ambient temperature: 0.1 mmole of cobalt complex I-c (R₁is ethylene diamine, X is dinitrophenyl anion; R₂â• H; R₃is tertiary butyl; there are organic base groups at position 3 and position 5 of one of the benzene rings in the ligand, n is 0) and 1 mole of propylene oxide. The reactor was then filled with carbon dioxide and the pressure was maintained constant at 2.0 MPa. The reaction was carried out at 25Â° C. for 6 hours to afford 23 grams of polycarbonate as a white solid. The average molecular weight of the polymer was determined by gel permeation chromatography to be 81,000 g/mol with a molecular weight distribution of 1.34. The polymer formed contained more than 99% carbonate linkages.

[Image Omitted]

Example 24

The following materials are added sequentially into a stainless steel high pressure reactor of volume of 200 mL at ambient temperature: 0.1 mmole of cobalt complex I-b (R₁is ethylene diamine, X is dinitrophenyl anion; R₂â• H; R₃and R₄are tertiary butyl; there are organic base groups at position 5 of the two benzene rings in the ligand, n is 0) and 1 mole of propylene oxide. The reactor was then filled with carbon dioxide and the pressure was maintained constant at 2.0 MPa. The reaction was carried out at 25Â° C. for 6 hours to afford 26 grams of polycarbonate as a white solid. The average molecular weight of the polymer was determined by gel permeation chromatography to be 83,000 g/mol with a molecular weight distribution of 1.19. The polymer formed contained more than 99% carbonate linkages. The polymer formed contained more than 99% carbonate linkages.

Example 25

The following materials are added sequentially onto a stainless steel high pressure reactor of volume of 200 mL at ambient temperature: 0.1 mmole of cobalt complex I-a (R₁is 2,3-butylene diamine, X is nitrate anion; R₂â• H; R₃and R₄are methoxyl group; R₁is tertiary butyl; there is an organic base group at position 3 of one of the benzene rings in the ligand, n is 2) and 1 mole of propylene oxide. The reactor was then filled with carbon dioxide and the pressure is maintained constant at 2.0 MPa. The reaction was carried out at 25Â° C. for 6 hours to afford 22 grams of polycarbonate as a white solid. The average molecular weight of the polymer was determined by gel permeation chromatography to be 73,000 g/mol with a molecular weight distribution of 1.14. The polymer formed contained more than 99% carbonate linkages.

Example 26

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the pressure was changed from 2.0 MPa to 0.1 MPa. The reaction was carried out at 25Â° C. for 10 hours to afford 25 grams of poly(propylene carbonate) with a molecular weight of 100,400 g/mol and a molecular weight distribution of 1.17. The polymer formed contained more than 99% carbonate linkages.

Example 27

The same equipment and reaction conditions were employed as in Example 10 with the same catalyst and the same conditions except that the pressure was changed from 2.0 MPa to 6.0 MPa. The reaction was carried out at 25Â° C. for 6 hours to afford 29 grams of poly(propylene carbonate) with a molecular weight of 125,000 g/mol and a molecular weight distribution of 1.25. The polymer formed contained more than 99% carbonate linkages.

TABLE E10Summary of Examples 10-27.Reaction ConditionsCatalystCat.EpoxidePTtExCatR1R2R3R4R5Xn(mmol)(mg)(mmol)MPapsi(deg C.)(h)10I-aCyHtButButBuNO₃2PO0.170.510002290256110.0214.1100022902524120.0085.64160022905010130.535310002290253140.170.5100022901000.5150.170.5100022901010260.170.510000.1152510270.170.51000637025616BO0.170.51000229025617OO0.170.510002290251018PO/CHO0.170.51000229050619CyHtButButBuOAc2PO0.170.21000229025620EnHtButButBuNO₃2PO0.165.11000229025621PhHtButButBuNO₃2PO0.169.91000229025625BuHOMeOMetBuNO₃2PO0.162.71000229025622I-bPrtBuDNP0PO0.1891000229025624I-bEnHtBuDNP0PO0.187.71000229025623I-cEnHtButBuDNP0PO0.188.210002290256ResultsPPCTOFMWg PC/kg PC/Exyield (g)conv. (%)TON(h^âˆ’1)(kDa)PDIg Catmol Cat.102726.426444411011.2383270112120.6102844292331.314891050121911.62326223263181.433692375134847.0940313531.313696143433333066601121.4482340151817.617631769141.4255180262524.52449244.91001.2355250272928.42840473.41251.3411290163126.72669444.91271.2440310173419.71974197.41091.44823401859837590193433.33330555951.3484340202928.428404731121.2446290212524.52449408921.2358250252221.52155359.1731.1351220222322.52253375811.3258230242625.52547424.4331.2296260232322.52253375.4811.3261230

While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been presented by way of example.